


Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	4818	544/360, 544/363, 544/367, 544/364, 544/370, 544/373, 544/374, 514/252.14, 514/253.05, 514/253.06, 514/253.09, 514/253.1, 514/254.02, 514/254.05, 514/254.03, 514/254.09, 514/254.1	USPAT	OR	OFF	2004/11/23 14:49
L2	28625	protease	USPAT	OR	OFF	2004/11/23 14:49
L3	301	I1 and I2	USPAT	OR	OFF	2004/11/23 14:49

=> d 11  
 L1 HAS NO ANSWERS  
 L1 STR



G1 Cb,Hy

Structure attributes must be viewed using STN Express query preparation.

=> s 11  
 SAMPLE SEARCH INITIATED 12:47:49 FILE 'REGISTRY'  
 SAMPLE SCREEN SEARCH COMPLETED - 962 TO ITERATE

100.0% PROCESSED 962 ITERATIONS 12 ANSWERS  
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
 BATCH \*\*COMPLETE\*\*  
 PROJECTED ITERATIONS: 17380 TO 21100  
 PROJECTED ANSWERS: 33 TO 447

L2 12 SEA SSS SAM L1

=> s 11 sss full  
 FULL SEARCH INITIATED 12:47:55 FILE 'REGISTRY'  
 FULL SCREEN SEARCH COMPLETED - 18672 TO ITERATE

100.0% PROCESSED 18672 ITERATIONS 312 ANSWERS  
 SEARCH TIME: 00.00.02

L3 312 SEA SSS FUL L1

=> file caplus  
 COST IN U.S. DOLLARS SINCE FILE TOTAL  
 ENTRY SESSION  
 FULL ESTIMATED COST 155.42 155.63

FILE 'CAPLUS' ENTERED AT 12:48:04 ON 23 NOV 2004  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the

American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Nov 2004 VOL 141 ISS 22  
FILE LAST UPDATED: 22 Nov 2004 (20041122/ED)


This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13  
L4 16 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2004 ACS ON STN  
ACCESSION NUMBER: 20031875291 CAPLUS  
DOCUMENT NUMBER: 139-350751  
TITLE: Preparation of pyrazolo[1,5-a]pyrimidine derivatives  
as NAD(P)H oxidase inhibitors  
INVENTOR(S): Seno, Kaoru; Nishi, Koichi; Matsuo, Yoshiyuki;  
Fujishita, Toshio  
PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan  
SOURCE: PCT Int. Appl., 240 pp.  
CODEN: PIKX02  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003091256	A1	20031106	WO 2003-JP5024	20030418
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, DE, DK, ES, FI, FR, GB, GR, HU, IE, IT, IJU, MC, NL, PT, RO, SE, SI, SK, TR, BE, BJ, CG, CI, CM, GA, GH, GQ, GW, ML, MR, NE, SN, TD, TZ				
PRIORITY APPLN. INFO.: JP 2002-121519				A 20020423
OTHER COUNTRIES:				




AB Title compds. I (R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub> = H, halo, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, etc.) and their pharmaceutically acceptable salts, useful in the prevention of or treatments for diseases relating to NAD(P)H, are prepared. Thus, N-2-cyclohexylphenyl 3-(3-chlorophenyl)pyrazolo[1,5-a]pyrimidin-5-amide was prepared in several

### steps from E

619304-05-1P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of pyrazolo[1,5-a]pyrimidine derivs. as NAD(P)H oxidase

L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN  
ACCESSION NUMBER: 2003:818397 CAPLUS  
DOCUMENT NUMBER: 139:292500  
TITLE: Synthesis of 1-(D-cyclopropylglycinyl)-4-(piperidin-4-yl)piperazine compounds and their effectiveness as inhibitors of the serine protease factor Xa for use in the treatment of thrombotic disorders in humans or animals  
INVENTOR(S): Wiley, Michael Robert; Engel, Gary Lowell  
PATENT ASSIGNEE(S): Eli Lilly and Company, USA  
SOURCE: PCT Int. Appl., 27 pp.  
CODEN: PIXX02  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003084929	A1	20031015	WO 2003-US7794	20030324
WO 2003084929	C1	20040521		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
CO, CR, CU, CZ, DE, DM, DO, EC, EE, ES, FI, GB, GD, GE, GH,				
GM, HR, HU, ID, IL, IN, IS, JR, KE, KG, KP, KR, LZ, LC, LR, MT,				
LS, LT, LU, LV, MA, MD, MG, ME, MN, MW, MX, MZ, NO, NZ, OM, PE,				
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,				
UA, UG, US, UZ, VC, VN, VU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MD, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,				
BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:		US 2002-368523P		P 20020401
GI				



AB The compds. of formula (I; R = H, F) or pharmaceutically acceptable salts thereof are Factor Xa inhibitors useful in the treatment of thrombotic disorders. Synthesis of the title compds. and their mono- or di-hydrochloride, maleate, or fumarate salts, and their efficacy as Factor Xa

Hahtee


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)  
 RN 619304-05-1 CAPLUS  
 CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[{[1R]-2-oxo-1-phenyl-2-(1-piperazinyl)ethyl}-3-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 109 THERE ARE 109 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT


L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)  
 inhibitors, is given. Thus, D-cyclopropylglycine was N-protected with the Boc-group (Boc =  $(\text{CH}_3)_2\text{CO}-$ ), which was then reacted with 1-(1-methylpropylidene-4-yl)aziridine; this intermediate was then N-protected to give a dihydrochloride salt, which was then exchanged with 4-methoxybenzyl chloride to give an  $\text{R}'=\text{Ar}$  salt, which could be used to prep the previously mentioned salts. In enzyme inhibition assays using human Factor Xa, title compds. had apparent  $\text{Km}$  (nmol/L) of  $\sim 14-35 \times 10^6$  L/mol. Title compds. were found to significantly elongate the partial thromboplastin time (no data).

IT 609768-52-7P 609768-53-8P  
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);  
BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);  
USES (Uses)  
the (preparation of D-cyclopropylglycinyl derivs. for use as inhibitors of  
serine protease factor Xa in the treatment of thrombotic disorders in



RN 609768-53-8 CAPLUS  
CN Benzamide, N-[1-(1-cyclopropyl-2-{[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxethyl}-3-fluoro-4-methoxy-(9CI)]-(CA INDEX NAME)

### Absolute stereochemistry




IT 609768-54-9P 609768-55-0P 609768-56-1P  
609768-57-2P 609768-58-3P 609768-59-4P  
609768-60-7P  
RU: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of D-cyclopropylglycyl derivs. for use as inhibitors of the 11/23/2004

L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)  
 serine protease factor Xa in the treatment of thrombotic disorders in  
 humans or animals)  
 RN 609768-54-9 CAPLUS  
 CN Benzamide, N-[(1R)-1-cyclopropyl-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-methoxy-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 609768-52-7  
CMF C23 H34 N4 O3


Absolute stereochemistry. Rotation (-).



CM 2

CRN 110-17-8  
CMF C4 H4 O4


Double bond geometry as shown.



RN 609768-55-0 CAPLUS  
 CN Benzamide, N-[(1R)-1-cyclopropyl-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-methoxy-, hydrochloride (4:5) (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



● 5/4 HCl

RN 609768-56-1 CAPLUS  
 CN Benzamide, N-[(1R)-1-cyclopropyl-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-3-fluoro-4-methoxy-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● x HCl


RN 609768-57-2 CAPLUS  
 CN Benzamide, N-[(1R)-1-cyclopropyl-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-methoxy-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 609768-52-7  
CMF C23 H34 N4 O3

Absolute stereochemistry. Rotation (-).


L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



CM 2

CRN 110-17-8  
CMF C4 H4 O4

Double bond geometry as shown.




RN 609768-58-3 CAPLUS  
 CN Benzamide, N-[(1R)-1-cyclopropyl-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-methoxy-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 609768-52-7  
CMF C23 H34 N4 O3

Absolute stereochemistry. Rotation (-).




CM 2

CRN 110-16-7  
CMF C4 H4 O4


Double bond geometry as shown.

L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 609768-59-4 CAPLUS  
 CN Benzamide, N-[(1R)-1-cyclopropyl-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-methoxy-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 609768-60-7 CAPLUS  
 CN Benzamide, N-[(1R)-1-cyclopropyl-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-methoxy-, (2Z)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 609768-52-7  
CMF C23 H34 N4 O3

Absolute stereochemistry. Rotation (-).



CM 2


CRN 110-16-7  
CMF C4 H4 O4

11/23/2004

Habte

L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Double bond geometry as shown.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN  
 ACCESSION NUMBER: 2002:964343 CAPLUS  
 DOCUMENT NUMBER: 138:29109  
 TITLE: Preparation of crystal forms of antithrombotic piperazine derivative  
 INVENTOR(S): Engel, Gary Lowell; Diserod, Benjamin Alan  
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA  
 SOURCE: PCT Int. Appl., 19 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 13  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002100847	A2	20021219	WO 2002-US16569	20020606
WO 2002100847	A3	20030821		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, HZ, SD, SL, SZ, T2, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CL, CM, GN, GW, ML, MR, NE, SN, TD, TG				
WO 2001096328	A1	20011220	WO 2001-GB2553	20010612
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1397348	A2	20040317	EP 2002-778933	20020606
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004534062	T2	20041111	JP 2003-502615	20020606
US 2003216403	A1	20031120	US 2003-296245	20030514
US 2004162295	A1	20040819	US 2003-477192	20031117
PRIORITY APPLN. INFO.:				
WO 2001-GB2553				W 20010612
US 2001-339295P				P 20011212
WO 2000-GB2302				W 20000613
GB 2000-30304				A 20001213
WO 2001-GB2566				W 20010612
WO 2002-US16569				W 20020606

AB 1-(Indole-6-carbonyl-*D*-phenylglycyl)-4-(1-methylpiperidin-4-yl)piperazine difumarate forms a stable crystalline salt and is an inhibitor of the serine protease and Factor Xa, useful in the treatment of cardiovascular disorders, especially a thrombotic disorder.  
 IT 478279-46-BP

L4 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)  
 RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); SPP (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses); (prepns. of cryst. forms of antithrombotic (indolecarbonyl-phenylglycyl) (methylpiperidinyl)piperazine difumarate)


RN 478279-46-8 CAPLUS

CN 1H-Indole-6-carboxamide, N-[(1R)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-phenylethyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 313489-71-3  
CMF C27 H33 N5 O2


Absolute stereochemistry. Rotation (-).



CM 2

CRN 110-17-8  
CMF C4 H4 O4

Double bond geometry as shown.



IT 313489-71-3


RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of crystalline forms of antithrombotic (indolecarbonyl-phenylglycyl) (methylpiperidinyl)piperazine difumarate)

RN 313489-71-3 CAPLUS


CN 1H-Indole-6-carboxamide, N-[(1R)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


L4 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)









RN 473913-73-4 CAPLUS  
 CN Benzamide, 4-benzoyl-N-[2-[4-[1,5-dioxo-5-(4-phenyl-1-piperazinyl)pentyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)




RN 473913-75-6 CAPLUS  
 CN Benzamide, 4-acetyl-N-[2-[4-[1,4-dioxo-4-(4-phenyl-1-piperazinyl)butyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)



RN 473913-76-7 CAPLUS  
 CN Benzamide, 4-acetyl-N-[2-[4-[1,5-dioxo-5-(4-phenyl-1-piperazinyl)pentyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)




RN 473913-82-5 CAPLUS  
 CN Benzamide, 4-benzoyl-N-[2-[4-[4-(4-methyl-1-piperazinyl)-1,4-dioxobutyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)



OTHER SOURCE(S): MARPAT 136:355487  
 GI

Habte




AB Title compds. I [R1, R2 = H, OH, alkoxy, alkyl, aminoalkyl, hydroxalkyl, alkoxyalkyl, alkoxy carbonyl, acyl, acylmethoxy carbonyl or alkylamino optionally substituted by hydroxy, alkylamino, alkoxyl, oxo, aryl, cycloalkyl; R3 = R1, R2, amino, halo, cyano, nitro, thiol, alkylthio, alkylsulfonyl, alkylsulfonyl, alkylsulfonamido, alkylaminosulfonyl, haloalkyl, haloalkyl; X = C, N, O, S, CO, C(R1)2, N(R1) with at least one X being C, CO, C(R1)2, with the proviso that if the benzamidine group is unsubstituted and the X-X group is -CH2C(R1)2-, then R1 = H or attached to the alkylene carbon atom by a heteroatom; L = organic linker containing 1-5 backbone atoms selected from C, N, O and S, or a branched alkyl or cyclic group; Y = N, C(R1)2, YL = cyclic group Cy = (un)saturated, (poly)cyclic, (hetero)cyclic group optionally substituted by groups R3 or Ph optionally substituted by R3; Lp = lipophilic alkyl, heterocyclic, alkenyl, alkaryl, (poly)cycloalkyl, cycloalkenyl, aryl, aralkyl, haloalkyl, or a combination of two or more such groups optionally substituted by oxa, oxo, aza, thio, halo, amino, hydroxy or by R3; D = H bond donor group; n = 0-2, or corresponding compds. in which the (un)substituted aminomethyl group (R1R2N(+)(=N)R1) is replaced with an (un)substituted aminomethyl group, or their physiol. tolerable salts were prepared as serine protease inhibitors useful as antithrombotic agents. 3-Aminido- and 3-(aminomethyl)benzoyl-D-phenylglycine 4-aminomethylcyclohexylmethylamide are among 190 compds. synthesized.

IT 221237-68-9P 221237-74-7P 221237-81-6P  
 221237-90-7P 221237-98-5P 221238-06-8P  
 221240-62-6P 221240-91-1P 221240-97-7P  
 221241-03-8P 221241-09-4P 221241-14-1P  
 221241-19-6P 221241-24-3P 221241-29-8P  
 221242-18-8P 221242-26-8P 221242-30-4P  
 221242-34-8P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of meta-benzamidine derivs. of amino acids or dipeptides as serine protease inhibitors)


CN 221237-68-9 CAPLUS  
 Benzamide, N-[1(R)-2-[4-(4-acetylphenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]-3-(aminomethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221237-74-7 CAPLUS  
 CN Benzamide, 3-(aminoiminomethyl)-N-[(1R)-2-[4-(4-methoxyphenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221237-81-6 CAPLUS  
 CN Benzamide, 3-(aminoiminomethyl)-N-[(1R)-2-[4-(4-chlorophenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221237-90-7 CAPLUS  
 CN Benzamide, 3-(aminoiminomethyl)-N-[(1R)-2-oxo-1-phenyl-2-(4-phenyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221240-91-1 CAPLUS  
 CN Benzamide, 3-(aminoiminomethyl)-N-[(1R)-2-[4-(4-nitrophenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221240-97-7 CAPLUS  
 CN Benzamide, 3-(aminoiminomethyl)-N-[(1R)-2-[4-(4-aminophenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221241-03-8 CAPLUS  
 CN Benzamide, 3-(aminoiminomethyl)-N-[(1R)-2-[4-(4-fluorophenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221237-98-5 CAPLUS  
 CN Benzamide, 3-(aminoiminomethyl)-N-[(1R)-2-[4-(4-methoxyphenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221238-06-8 CAPLUS  
 CN Benzamide, 3-(aminoiminomethyl)-N-[(1R)-2-[4-(4-benzoyl-1-piperazinyl)-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221240-62-6 CAPLUS  
 CN Carboxamic acid, [(3-[(1R)-2-[4-(4-chlorophenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]amino)carbonylphenyl]iminomethyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221241-09-4 CAPLUS  
 CN Benzamide, 3-(aminoiminomethyl)-N-[(1R)-2-oxo-1-phenyl-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221241-14-1 CAPLUS  
 CN Benzamide, 3-(aminoiminomethyl)-N-[(1R)-2-oxo-1-phenyl-2-(4-(2-pyridinyl)-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221241-19-6 CAPLUS  
 CN Benzamide, 3-(aminoiminomethyl)-N-[(1R)-2-oxo-1-phenyl-2-[4-(phenylmethyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221241-24-3 CAPLUS  
 CN Benzamide, 3-[(aminoiminomethyl)-N-[(1R)-2-[4-(3-chlorophenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221241-29-8 CAPLUS  
 CN Benzamide, 3-[(aminoiminomethyl)-N-[(1R)-2-[4-(2-chlorophenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221242-18-8 CAPLUS  
 CN Propionic acid, 2,2-dimethyl-, [[[[(3-[(1R)-2-[4-(4-chlorophenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]amino]carbonyl]phenyl]iminomethyl]amino]carbonyl]oxy]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




—Bu-t  
 RN 221242-26-8 CAPLUS  
 CN Carbamic acid, [[3-[[[(1R)-2-[4-(4-chlorophenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]amino]carbonyl]phenyl]iminomethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221242-30-4 CAPLUS  
 CN Carbamic acid, [[3-[[[(1R)-2-[4-(4-chlorophenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]amino]carbonyl]phenyl]iminomethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221242-34-8 CAPLUS  
 CN Benzamide, 3-[(acetylamino)iminomethyl]-N-[(1R)-2-[4-(4-chlorophenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



TITLE: PROSELECT: Combining Structure-Based Drug Design and Array-Based Chemistry for Rapid Lead Discovery. 2. The Development of a Series of Highly Potent and Selective Factor Xa Inhibitors

AUTHOR(S): Liebeschuetz, John W.; Jones, Stuart D.; Morgan, Philip J.; Murray, Chris W.; Rimmer, Andrew D.; Roscoe, Jonathan M. E.; Waszkowycz, Bohdan; Welsh, Pauline M.; Wylie, William A.; Young, Stephen C.; Martin, Harry; Mahler, Jacqui; Brady, Leo; Wilkinson, Kay

CORPORATE SOURCE: Protherics Molecular Design, Macclesfield, SK11 0JL, UK

SOURCE: Journal of Medicinal Chemistry (2002), 45(6), 1221-1232

PUBLISHER: JCMAR; ISSN: 0022-2623

DOCUMENT TYPE: American Chemical Society

LANGUAGE: Journal

English

AB In silico screening of combinatorial libraries prior to synthesis promises to be a valuable aid to lead discovery. PROSELECT, a tool for the virtual screening of libraries for fit to a protein active site, has been used to find novel leads against the serine protease factor Xa. A small seed template was built upon using three iterations of library design, virtual screening, synthesis, and biol. testing. Highly potent mol. with selectivity for factor Xa over other serine proteases were rapidly obtained.

IT 410527-83-2P

RL PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(combining structure-based drug design and array-based chemical for development of a series of potent and selective factor Xa inhibitors)

RN 410527-83-2 CAPLUS


CN Benzamide, 3-[(aminoiminomethyl)-N-[(1R)-2-[4-(4-chlorophenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 221237-81-6

CMF C26 H26 Cl N5 O2

Absolute stereochemistry.



L4 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

CRN 76-05-1  
CMF C2 H F3 O2

REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN  
 ACCESSION NUMBER: 2001:923784 CAPLUS  
 DOCUMENT NUMBER: 136:54020  
 TITLE: Preparation of amino acid derivatives as serine protease inhibitors  
 INVENTOR(S): Liebeschuetz, John Walter; Murray, Christopher; Young, Stephen Clinton; Camp, Nicholas Paul; Jones, Stuart Donald; Wylie, William Alexander; Masters, John Joseph; Wiley, Michael Robert; Sheehan, Scott Martin; Engel, David Binenbaum; Watson, Brian; Morgan, Guzzo, Peter Robert; Mayer, Michael John  
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA  
 SOURCE: PCT Int. Appl., 191 pp.  
 CODEN: PIXX02  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 13  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE		
WO 2001096323	A1	20011220	WO 2001-GB2553	20010612		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MH, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZB, ZM, ZR, ZT, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, BG, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, BG, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	WO 200016971	A2	20011221	WO 2000-GB2302	20000613
WO 2000076971	A3	20010822				
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MH, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZB, ZM, ZR, ZT, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, IE, IT, LU, MC, NL, PT, SE, BF, BJ, BG, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	WO 2000076971	A3	20010822			
CA 2411805	A	20011220	CA 2001-2411805	20010612		
EP 1289972	A1	20030312	EP 2001-936686	20010612		
EP 1289972	B1	20040908				
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR	EP 1289972	B1	20040908			
BR 2001011451	A	20030624	BR 2001-11451	20010612		
JP 2004503547	T2	20040205	JP 2002-510466	20010612		
NZ 521896	A	20040730	NZ 2001-521896	20010612		
AT 275554	E	20040915	AT 2001-936686	20010612		
US 2003055246	A1	20030320	US 2002-30187	20020204		
WO 2002100847	A2	20021219	WO 2002-US16569	20020606		
WO 2002100847	A3	20030821				
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,						

L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)  
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZB, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG

EP 1397348 A2 20040317 EP 2002-778933 20020606  
 R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP 2004534062 T2 20041111 JP 2003-503615 20020606  
 NO 200205665 A 20021125 NO 2002-5665 20021125  
 US 2003216403 A1 20031120 US 2003-296245 20030514  
 US 2004162295 A1 20040819 US 2003-477192 20031117  
 US 2004142963 A1 20040722 US 2004-754923 20040112  
 US 2004176363 A1 20040909 US 2004-803157 20040318  
 PRIORITY APPLN. INFO.: WO 2000-GB2302 20000613  
 GB 2000-30304 A 20001213  
 GB 1999-13823 A 19990614  
 US 1999-142064P F 19990702  
 GB 1999-18741 A 19990609  
 GB 1999-29553 A 19991214  
 WO 2001-GB2553 W 20010612  
 WO 2001-GB2566 W 20010612  
 US 2001-339295P F 20011212  
 US 2002-30187 A1 20022024  
 WO 2002-US16569 W 20020606


OTHER SOURCE(S): MARPAT 136:54020

AB Compds. R2-X-Y(Cy)-L-Lp(D)n [R2 is a 5- or 6-membered aromatic carbon ring optionally interrupted by a N, O or S ring atom, optionally substituted at the 3 and/or 4 position or forms a fused ring system at these positions, which is an optionally substituted 5- or 6-membered carbocyclic or heterocyclic ring, or substituted at the position alpha to X-Y, with the proviso that R2 can not be aminoisoquinolyl; X is a C, N, O or S atom or a CO, CR1a, C(R1a)2 or CR1a group (at least one X is C, CO, CR1a or C(R1a)2, where R1a represents H, OH, alkoy, alkyl, aminalkyl, hydroxalkyl, alkoxyalkyl, alkoxycarbonyl, alkylaminocarbonyl, alkoxycarbonylamin, acyloxymethoxycarbonyl or alkylaminocarbonyl, substituted by OH, alkylamin, alkoy, oxo, aryl or cycloalkyl; Y is a N and a CR1b group (R1b defined as for R1a); Cy is an (1R)-substituted, (un)saturated, mono- or polycyclic, homo- or heterocyclic group; -L-Lp(D)n is 4-substituted 1-piperazinecarbonyl] or their physiol.-tolerable salts were prepared for use as serine protease inhibitors. Compds. of the invention were found to significantly elongate the partial thromboplastin time (prothrombin time). Thus, 1-(4-methoxybenzoyl)-D-phenylglycyl-4-phenylpiperazine was prepared in the first of 82 examples.

IT 301722-41-4P 301722-57-2P  
 RL: BYP (Byproduct); PREP (Preparation)  
 (preparation of amino acid derivs. as serine protease inhibitors)  
 RN 301722-41-4 CAPLUS  
 CN Benzamide, N-[(1S)-1-(2-chlorophenyl)-2-{4-(1-methyl-4-piperidinyl)-1-piperazinyl}-2-oxoethyl]-4-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 3B1722-57-2 CAPLUS  
 CN B:Indole-6-carboxamide, N-[(1S)-1-(2-chlorophenyl)-2-{4-(1-methyl-4-piperidinyl)-1-piperazinyl}-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 313489-70-2P 313489-71-3P 301720-62-3P  
 301720-64-5P 301721-10-4P 301721-12-6P  
 301721-27-3P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of amino acid derivs. as serine protease inhibitors)  
 RN 313489-70-2 CAPLUS  
 CN Benzamide, 4-methoxy-N-[(1R)-2-{4-(1-methyl-4-piperidinyl)-1-piperazinyl}-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 313489-71-3 CAPLUS  
 CN 1H-Indole-6-carboxamide, N-[(1R)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 381720-62-3 CAPLUS  
 CN 1H-Indole-6-carboxamide, N-[(1R)-2-oxo-1-phenyl-2-[4-(2-(4-pyridinyl)ethyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381720-64-5 CAPLUS  
 CN 1H-Indole-6-carboxamide, 3-chloro-N-[(1R)-2-oxo-1-phenyl-2-[4-(2-(4-pyridinyl)ethyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Absolute stereochemistry.




IT 313489-33-4P 313489-20-2P 313489-22-4P  
 313489-25-7P 313489-59-6P 313489-59-7P  
 313489-60-0P 313489-61-1P 313489-62-2P  
 313489-63-3P 313489-64-4P 313489-65-5P  
 313489-66-6P 313489-67-7P 313489-72-4P  
 313489-73-5P 313690-67-4P 381720-59-8P  
 381720-66-7P 381720-68-9P 381720-69-0P  
 381720-71-4P 381720-73-6P 381720-75-8P  
 381720-77-0P 381720-79-2P 381720-80-5P  
 381720-81-6P 381720-82-7P 381720-83-8P  
 381720-84-9P 381720-85-0P 381720-86-1P  
 381720-87-2P 381720-88-3P 381720-89-4P  
 381720-90-7P 381720-91-8P 381720-92-9P  
 381720-93-0P 381720-95-2P 381720-96-3P  
 381720-97-4P 381720-98-5P 381720-99-6P  
 381721-00-2P 381721-01-3P 381721-02-4P  
 381721-04-6P 381721-06-8P 381721-08-0P  
 381721-09-1P 381721-11-5P 381721-13-7P  
 381721-14-0P 381721-15-9P 381721-16-0P  
 381721-17-1P 381721-19-2P 381721-19-3P  
 381721-20-6P 381721-21-7P 381721-22-8P  
 381721-23-9P 381721-24-0P 381721-25-1P  
 381721-26-2P 381721-28-4P 381721-29-5P  
 381721-30-8P 381721-31-9P 381721-32-0P  
 381721-33-1P 381721-34-2P 381721-35-3P  
 381721-36-4P 381721-37-5P 381721-38-6P  
 381721-39-7P 381721-40-0P 381721-41-1P  
 381721-42-2P 381721-43-3P 381721-44-4P  
 381721-45-5P 381721-46-6P 381721-47-7P  
 381722-62-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of amino acid derivs. as serine protease inhibitors)


RN 313489-33-4 CAPLUS  
 CN Benzoic acid, 4-[(1R)-1-[(1H-indol-6-ylcarbonyl)amino]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 381721-10-4 CAPLUS  
 CN 1H-Indole-6-carboxamide, N-[(1R)-2-[4-(2-(3-fluoro-4-pyridinyl)ethyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 381721-12-6 CAPLUS  
 CN 1H-Indole-6-carboxamide, N-[(1R)-2-[4-(2-cyano-4-pyridinyl)ethyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 381721-27-3 CAPLUS  
 CN 1H-Indole-6-carboxamide, N-[(1R)-2-oxo-1-phenyl-2-[4-(2-phenylethyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 313489-20-2 CAPLUS  
 Benzamide, 4-methoxy-N-[(1R)-2-oxo-1-phenyl-2-[4-(4-piperidinylmethyl)-1-piperazinyl]ethyl]-, trifluoroacetate (2:5) (9CI) (CA INDEX NAME)




RN 313489-20-2 CAPLUS  
 Benzamide, 4-methoxy-N-[(1R)-2-oxo-1-phenyl-2-[4-(4-piperidinylmethyl)-1-piperazinyl]ethyl]-, trifluoroacetate (2:5) (9CI) (CA INDEX NAME)

CM 1

CRN 313489-19-9  
 CMF C26 H34 N4 O3

Absolute stereochemistry.




CM 2

CRN 76-05-1  
 CMF C2 H F3 O2



RN 313489-22-4 CAPLUS  
 Benzamide, 4-methoxy-N-[(1R)-2-[4-[[1-(1-methylethyl)-4-piperidinyl]methyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-, trihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 313489-25-7 CAPLUS  
 CN Benzamide, N-[(1R)-2-[4-(2-cyclopentylethyl)-1-piperazinyl]-2-oxo-1-phenylethyl]-4-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 313489-58-6 CAPLUS  
 CN Benzamide, 4-methoxy-N-[(1R)-2-oxo-1-phenyl-2-[4-(2-pyridinylmethyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313489-59-7 CAPLUS  
 CN Benzamide, 4-methoxy-N-[(1R)-2-oxo-1-phenyl-2-[4-(3-pyridinylmethyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313489-60-0 CAPLUS  
 CN Benzamide, 4-methoxy-N-[(1R)-2-oxo-1-phenyl-2-[4-(4-pyridinylmethyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313489-61-1 CAPLUS  
 CN Benzamide, 4-methoxy-N-[(1R)-2-oxo-1-phenyl-2-[4-(2-phenylethyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313489-62-2 CAPLUS  
 CN Benzamide, N-[(1R)-2-[4-(1-ethylpropyl)-1-piperazinyl]-2-oxo-1-phenylethyl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313489-63-3 CAPLUS  
 CN Benzamide, N-[(1R)-2-(4-cyclopentyl-1-piperazinyl)-2-oxo-1-phenylethyl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313489-64-4 CAPLUS  
 CN Benzamide, 4-methoxy-N-[(1R)-2-oxo-1-phenyl-2-[4-(tetrahydro-2H-thiopyran-4-yl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313489-65-5 CAPLUS  
 CN Benzamide, N-[(1R)-2-[4-(2,3-dihydro-1H-inden-2-yl)-1-piperazinyl]-2-oxo-1-phenylethyl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313489-66-6 CAPLUS  
 CN Benzamide, 4-methoxy-N-[(1R)-2-oxo-1-phenyl-2-[4-(phenylmethyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313489-67-7 CAPLUS  
 CN Benzamide, N-[(1R)-2-[4-(cyclohexylmethyl)-1-piperazinyl]-2-oxo-1-phenylethyl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313489-72-4 CAPLUS  
 CN 1H-Indole-6-carboxamide, 3-methyl-N-[(1R)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313489-73-5 CAPLUS  
 CN 1H-Indole-6-carboxamide, 3-chloro-N-[(1R)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313690-67-4 CAPLUS  
 CN Benzamide, 4-methoxy-N-[(1R)-2-[4-(4-methylcyclohexyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381720-59-8 CAPLUS  
 CN Benzamide, 4-methoxy-N-[(1R)-2-oxo-1-phenyl-2-[4-[2-(4-pyridinyl)ethyl]-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)


RN 381720-69-0 CAPLUS  
 CN 1H-Indole-6-carboxamide, 3-methyl-N-[(1R)-2-oxo-1-phenyl-2-[4-[2-(4-pyridinyl)ethyl]-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 381720-71-4 CAPLUS  
 CN Benzamide, 4-methoxy-N-[(1R)-2-oxo-1-phenyl-2-[4-[2-(2-pyridinyl)ethyl]-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 381720-73-6 CAPLUS  
 CN 1H-Indole-6-carboxamide, 3-chloro-N-[(1R)-2-oxo-1-phenyl-2-[4-[2-(2-pyridinyl)ethyl]-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381720-75-8 CAPLUS  
 CN 1H-Indole-6-carboxamide, N-[(1R)-2-oxo-1-phenyl-2-[4-(2-(2-

Habte


Absolute stereochemistry.



●2 HCl


RN 381720-66-7 CAPLUS  
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R)-2-oxo-1-phenyl-2-[4-(4-pyridinyl)ethyl]-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 381720-69-9 CAPLUS  
 CN 1H-Indole-2-carboxamide, N-[(1R)-2-oxo-1-phenyl-2-[4-(4-pyridinyl)ethyl]-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



Absolute stereochemistry.




RN 381720-77-0 CAPLUS  
 CN Benzamide, 4-methoxy-N-[(2-oxo-1-(2-pyridinyl)-2-[4-(2-pyridinyl)ethyl]-1-piperazinyl]ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)




●3 HCl

RN 381720-79-2 CAPLUS  
 CN 1H-Indole-6-carboxamide, 3-chloro-N-[(2-oxo-1-(2-pyridinyl)-2-[4-(2-pyridinyl)ethyl]-1-piperazinyl]ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)




●3 HCl

RN 381720-80-5 CAPLUS  
 CN 1H-Indole-6-carboxamide, 3-methyl-N-[(2-oxo-1-(2-pyridinyl)-2-[4-(2-pyridinyl)ethyl]-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 381720-81-6 CAPLUS  
 CN 1H-Indole-6-carboxamide, N-[2-oxo-1-(2-pyridinyl)-2-[4-(2-(4-pyridinyl)ethyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 381720-82-7 CAPLUS  
 CN 1H-Indole-6-carboxamide, N-[1(R)-2-oxo-1-phenyl-2-[4-(2-(3-pyridinyl)ethyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 381720-83-8 CAPLUS  
 CN 1H-Indole-6-carboxamide, N-[1(R)-2-oxo-1-phenyl-2-[4-(2-pyrazinylethyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



•2 HCl

RN 381720-87-2 CAPLUS  
 CN 1H-Indole-6-carboxamide, N-[1(R)-2-oxo-1-phenyl-2-[4-(2-(1H-pyrazol-4-yl)ethyl)-1-piperazinyl]ethyl]-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



•2 HCl


RN 381720-88-3 CAPLUS  
 CN 1H-Indole-6-carboxamide, N-[1(R)-2-oxo-1-phenyl-2-[4-(2-(3-pyridinyl)ethyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 381720-89-4 CAPLUS  
 CN Benzamide, 4-methoxy-N-[1-(2-methoxyphenyl)-2-oxo-2-[4-(2-(4-

Habte




RN 381720-84-9 CAPLUS  
 CN 1H-Indole-6-carboxamide, N-[1(R)-2-[4-(2-(1H-imidazol-1-yl)ethyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 381720-85-0 CAPLUS  
 CN 1H-Indole-6-carboxamide, N-[1(R)-2-oxo-1-phenyl-2-[4-(2-(1H-pyrazol-1-yl)ethyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 381720-86-1 CAPLUS  
 CN 1H-Indole-6-carboxamide, N-[1(R)-2-[4-(2-(1H-imidazol-4-yl)ethyl)-1-piperazinyl]-2-oxo-1-phenylethyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 381720-90-7 CAPLUS  
 CN 1H-Indole-6-carboxamide, N-[1-(2-methoxyphenyl)-2-oxo-2-[4-(2-(3-pyridinyl)ethyl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



•2 HCl

RN 381720-91-8 CAPLUS  
 CN Benzamide, 3-amino-N-[1(R)-1-[2-(aminocarbonyl)phenyl]-2-oxo-2-[4-(2-phenylethyl)-1-piperazinyl]ethyl]-4-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381720-92-9 CAPLUS  
 CN Benzamide, 3-amino-N-[1(R)-1-[2-(aminocarbonyl)phenyl]-2-oxo-2-[4-(phenylmethyl)-1-piperazinyl]ethyl]-4-chloro- (9CI) (CA INDEX NAME)


11/23/2004

## Absolute stereochemistry.



RN 381720-93-0 CAPLUS  
 CN Benzamide, 4-methoxy-N-[(1R)-2-[4-[(1-methyl-4-piperidinyl)methyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

## Absolute stereochemistry.




RN 381720-95-2 CAPLUS  
 CN Benzamide, 4-methoxy-N-[(1R)-2-oxo-1-phenyl-2-[4-(1H-pyrrol-3-yl)-1-piperazinyl]ethyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 381720-94-1  
CNP C24 H26 N4 O3

## Absolute stereochemistry.




CM 2

CRN 76-05-1  
CNP C2 H3 F3 O2


RN 381720-96-3 CAPLUS  
 CN Benzamide, 4-methoxy-N-[(1R)-2-[4-(1-methyl-1H-pyrrol-3-yl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

## Absolute stereochemistry.




RN 381720-97-4 CAPLUS  
 CN Benzamide, 4-methoxy-N-[(1R)-2-[4-(1-(1-methylethyl)-1H-pyrrol-3-yl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

## Absolute stereochemistry.




RN 381720-98-5 CAPLUS  
 CN Benzamide, 4-methoxy-N-[(1R)-2-oxo-1-phenyl-2-[4-(1-propylbutyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

## Absolute stereochemistry.




RN 381720-99-6 CAPLUS  
 CN Benzamide, 4-methoxy-N-[(1R)-2-oxo-1-phenyl-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

## Absolute stereochemistry.




RN 381721-00-2 CAPLUS  
 CN Benzamide, N-[(1R)-2-(4-cyclohexyl-1-piperazinyl)-2-oxo-1-phenylethyl]-4-methoxy- (9CI) (CA INDEX NAME)

## Absolute stereochemistry.



RN 381721-01-3 CAPLUS  
 CN 1H-Indole-6-carboxamide, 3-chloro-N-[(1R)-2-oxo-1-phenyl-2-[4-(4-piperidinylmethyl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)


## Absolute stereochemistry.



● 2 HCl

RN 381721-02-4 CAPLUS  
 CN 1H-Indole-6-carboxamide, 3-methyl-N-[(1R)-2-oxo-1-phenyl-2-[4-(4-piperidinylmethyl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)

## Absolute stereochemistry.




● 2 HCl

RN 381721-04-6 CAPLUS  
 CN Benzamide, 4-chloro-N-[(1R)-2-oxo-1-phenyl-2-[4-(phenylmethyl)-1-piperazinyl]ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

CN 381721-03-5  
CMF C26 H26 Cl N3 O2

Absolute stereochemistry.




CM 2

CRN 76-05-1  
CMF C26 H32 Cl N3 O2RN 381721-06-8 CAPLUS  
CN Benzamide, 4-chloro-N-[(1R)-2-oxo-1-phenyl-2-{4-(2-phenylethyl)-1-piperazinyl}ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 381721-05-7  
CMF C27 H28 Cl N3 O2

Absolute stereochemistry.



CM 2


L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

CN 76-05-1  
CMF C2 H3 F3 O2RN 381721-08-0 CAPLUS  
CN Benzamide, 4-chloro-N-[(1R)-2-[4-(cyclohexylmethyl)-1-piperazinyl]-2-oxo-1-phenylethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 381721-07-9  
CMF C26 H32 Cl N3 O2

Absolute stereochemistry.




CM 2

CRN 76-05-1  
CMF C26 H32 Cl N3 O2RN 381721-09-1 CAPLUS  
CN 1H-Indole-6-carboxamide, N-[(1R)-2-oxo-1-phenyl-2-{4-[2-(2-thiazolyl)ethyl]-1-piperazinyl}ethyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● x HCl

RN 381721-11-5 CAPLUS  
CN 1H-Indole-6-carboxamide, N-[(1R)-2-[4-(2-(3-fluoro-4-pyridinyl)ethyl)-1-piperazinyl]-2-oxo-1-phenylethyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● x HCl

RN 381721-13-7 CAPLUS  
CN Benzamide, N-[(1-(2-chlorophenyl)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl)-4-methoxy-, hydrochloride (9CI) (CA INDEX NAME)


● x HCl

Habte


L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 381721-14-8 CAPLUS  
CN Benzamide, N-[(1R)-1-(2-chlorophenyl)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-methoxy-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● x HCl


RN 381721-15-9 CAPLUS  
CN 1H-Indole-6-carboxamide, N-[(1-(2-chlorophenyl)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

● 2 HCl

RN 381721-16-0 CAPLUS  
CN 1H-Indole-6-carboxamide, N-[(1R)-1-(2-chlorophenyl)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.

11/23/2004




●2 HCl


RN 381721-17-1 CAPLUS  
 CN 1H-Indole-6-carboxamide, N-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-(8-quinolinyl)ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)




RN 381721-18-2 CAPLUS  
 CN 1H-Indole-6-carboxamide, 3-chloro-N-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-(8-quinolinyl)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)



RN 381721-19-3 CAPLUS  
 CN 1H-Indole-6-carboxamide, 3-methyl-N-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-(8-quinolinyl)ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)




RN 381721-20-6 CAPLUS  
 CN Benzamide, 4-methoxy-N-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-[2-(trifluoromethyl)phenyl]ethyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 381721-21-7 CAPLUS  
 CN Benzamide, 4-methoxy-N-[(1R)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-[2-(trifluoromethyl)phenyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 381721-22-8 CAPLUS  
 CN 1H-Indole-6-carboxamide, N-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-[2-(trifluoromethyl)phenyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

Habte

RN 381721-23-9 CAPLUS  
 CN Benzamide, N-[(1R)-1-cyclopentyl-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-methoxy-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●2 HCl

RN 381721-24-0 CAPLUS  
 CN 1H-Indole-6-carboxamide, N-[(1R)-1-cyclopentyl-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 381721-25-1 CAPLUS  
 CN Benzamide, N-[(1R)-1-cyclohexyl-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-methoxy-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

11/23/2004


L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



●2 HCl

RN 381721-26-2 CAPLUS  
 CN 1H-indole-6-carboxamide, N-[(1R)-1-cyclohexyl-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.




●2 HCl

RN 381721-29-4 CAPLUS  
 CN Benzamide, 4-methoxy-N-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-(2-thiazolyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 381721-29-5 CAPLUS  
 CN Benzamide, N-[1-benzo[b]thien-3-yl-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 381721-30-8 CAPLUS  
 CN Benzamide, 4-methoxy-N-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-1-(1-naphthalenyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 381721-31-9 CAPLUS  
 CN 1H-Indole-6-carboxamide, N-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-1-(1-naphthalenyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 381721-32-0 CAPLUS  
 CN Benzamide, 4-methoxy-N-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-1-[2-(methylsulfonyl)phenyl]-2-oxoethyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 381721-33-1 CAPLUS  
 CN Benzamide, 4-methoxy-N-[2-oxo-2-[4-(2-pyridinyl)ethyl]-1-piperazinyl]-1-

Habte

L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)  
(5-thiazolyl)ethyl-, dihydrochloride (9CI) (CA INDEX NAME)

●2 HCl


RN 381721-34-2 CAPLUS  
 CN Benzamide, 4-methoxy-N-[1-(2-methyl-4-thiazolyl)-2-oxo-2-[4-(2-pyridinyl)ethyl]-1-piperazinyl]ethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 381721-35-3 CAPLUS  
 CN Benzamide, N-[1-(2-amino-4-thiazolyl)-2-oxo-2-[4-(2-pyridinyl)ethyl]-1-piperazinyl]ethyl-4-methoxy-, dihydrochloride (9CI) (CA INDEX NAME)


11/23/2004



●2 HCl

RN 381721-36-4 CAPLUS  
 CN 1H-Indole-6-carboxamide, N-[(1R)-2-oxo-1-phenyl-2-[4-(4-pyridinyl)ethyl]-1-piperazinyl]ethyl-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●2 HCl

RN 381721-37-5 CAPLUS  
 CN 1H-Indole-6-carboxamide, 3-chloro-N-[(1R)-2-oxo-1-phenyl-2-[4-(4-pyridinyl)ethyl]-1-piperazinyl]ethyl-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●2 HCl

RN 381721-38-6 CAPLUS  
 CN 1H-Indole-6-carboxamide, N-[(1R)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-phenylethyl]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●2 HCl

RN 381721-39-7 CAPLUS  
 CN 1H-Indole-6-carboxamide, N-[(1R)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-phenylethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HCl

RN 381721-40-0 CAPLUS  
 CN 1H-Indole-6-carboxamide, N-[(1R)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-phenylethyl]-, (22)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 313489-71-3  
CMF C27 H33 N5 O2


Absolute stereochemistry. Rotation (-).



CM 2

CRN 110-16-7  
CMF C4 H4 O4


Double bond geometry as shown.



RN 381721-41-1 CAPLUS  
 CN 1H-Indole-6-carboxamide, N-[(1R)-2-[4-(2-cyano-4-pyridinyl)ethyl]-1-piperazinyl]-2-oxo-1-phenylethyl-, hydrochloride (9CI) (CA INDEX NAME)

Habte


Absolute stereochemistry.



● HCl


RN 381721-42-2 CAPLUS  
 CN 1H-Indole-6-carboxamide, N-[(1R)-2-oxo-1-phenyl-2-[4-(2-phenylethyl)-1-piperazinyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 381721-43-3 CAPLUS  
 CN Benzamide, N-[1-benzo[b]thien-3-yl-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-methoxy-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 381721-44-4 CAPLUS  
 CN Benzamide, 4-methoxy-N-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-1-(1-naphthalenyl)-2-oxoethyl]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 381721-45-5 CAPLUS  
 CN Benzamide, N-[(1R)-1-(2-chlorophenyl)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-[2-(trifluoromethyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)  
 RN 381722-62-9 CAPLUS  
 CN Benzamide, 4-methoxy-N-[(1S)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-[2-(trifluoromethyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 381722-55-0 381722-56-1 381722-58-3  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of amino acid derivs. as serine protease inhibitors)

RN 381722-55-0 CAPLUS  
 CN Benzamide, N-[(2-chlorophenyl)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 381722-56-1 CAPLUS  
 CN 1H-Indole-6-carboxamide, N-[1-(2-chlorophenyl)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 381722-58-3 CAPLUS  
 CN Benzamide, 4-methoxy-N-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-[2-(trifluoromethyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)

Habte





RN 381721-46-6 CAPLUS  
 CN 1H-Indole-6-carboxamide, N-[(1R)-1-(2-chlorophenyl)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 381721-47-7 CAPLUS  
 CN Benzamide, 4-methoxy-N-[(1R)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-[2-(trifluoromethyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 313490-70-9P 313490-72-1P 313490-73-2P  
 313490-74-3P 381722-45-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of amino acid derivs. as serine protease inhibitors)

RN 313490-70-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2R)-[(4-methoxybenzoyl)amino]phenylacetyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313490-72-1 CAPLUS  
 CN Benzamide, 4-methoxy-N-[(1R)-2-oxo-1-phenyl-2-(1-piperazinyl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313490-71-0  
 CHF C20 H23 N3 O3

Absolute stereochemistry.



CH 2

CRN 76-05-1


11/23/2004

L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)  
 CMR C2 H F3 O2




RN 313490-73-2 CAPLUS  
 CN 1-Piperidinecarboxylic acid, 4-[(4-[(2R)-{(4-methoxybenzoyl)amino}phenylacetyl]-1-piperazinyl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313490-74-3 CAPLUS  
 CN Benzamide, N-[(1R)-2-[(4-(2-cyclopentylethyl)-1-piperazinyl)-2-oxo-1-phenylethyl]-4-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381722-45-0 CAPLUS  
 CN 1H-Pyrrole-1-carboxylic acid, 3-[(4-[(2R)-{(4-methoxybenzoyl)amino}phenylacetyl]-1-piperazinyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN  
 2001:177455 CAPLUS  
 DOCUMENT NUMBER: 134:353501  
 TITLE: The design of phenylglycine containing benzamidine carboxamides as potent and selective inhibitors of factor Xa  
 AUTHOR(S): Jones, S. D.; Liebeschuetz, J. W.; Morgan, P. J.; Murray, C. W.; Rimmer, A. D.; Roscoe, J. M. E.; Waszkowycz, B.; Welsh, P. M.; Wyllie, V. A.; Young, S. C.; Martin, H.; Mahler, J.; Brady, L.; Wilkinson, K. Protherics Molecular Design, Macclesfield, SK11 0JL, UK  
 CORPORATE SOURCE: Bioorganic & Medicinal Chemistry Letters (2001), 11(5), 733-736  
 SOURCE: CODEN: BMCLB; ISSN: 0960-894X  
 PUBLISHER: Elsevier Science Ltd.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 134:353501  
 AB Factor Xa, a critical serine protease in the blood coagulation cascade, has become a target for inhibition as a strategy for the invention of novel anti-thrombotic agents. Here we describe the development of phenylglycine containing benzamidine carboxamides as novel, potent and selective inhibitors of factor Xa. A number of highly focused libraries of compds. have been designed and synthesized giving rapid access to a series of potent and selective inhibitors of factor Xa. Key to the potency of these compds. is the lipophilic interaction between phenylglycine residue and the 'disulfide' pocket comprising Gln192, Cys191, Cys220 and Gly218.  
 IT 221237-90-7P 221238-06-8P 221241-03-8P  
 221241-09-4P 221241-19-6P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (preparation of libraries of phenylglycine containing benzamidine carboxamides as selective inhibitors of factor Xa)  
 RN 221237-90-7 CAPLUS  
 CN Benzamide, 3-(aminoiminomethyl)-N-[(1R)-2-oxo-1-phenyl-2-(4-phenyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 221238-06-8 CAPLUS  
 CN Benzamide, 3-(aminoiminomethyl)-N-[(1R)-2-(4-benzoyl-1-piperazinyl)-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 221241-03-8 CAPLUS  
 CN Benzamide, 3-(aminoiminomethyl)-N-[(1R)-2-[(4-(4-fluorophenyl)-1-piperazinyl)-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221241-09-4 CAPLUS  
 CN Benzamide, 3-(aminoiminomethyl)-N-[(1R)-2-oxo-1-phenyl-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 221241-19-6 CAPLUS  
 CN Benzamide, 3-(aminoiminomethyl)-N-[(1R)-2-oxo-1-phenyl-2-[4-(phenylmethyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:167219 CAPLUS

DOCUMENT NUMBER: 135:5586

TITLE: Novel non-peptide GPIIb/IIIa antagonists: synthesis and biological activities of 2-[4-(2-(4-amidinobenzoylamino)-2'-substituted)acetyl]-3-(2-methoxy-2-oxoethyl)-2-oxopiperazinylacetic acids

AUTHOR(S): Kitamura, Shuji; Fukushi, Hideki; Miyawaki, Toshio; Kawamura, Masaki; Terashita, Zen-ichi; Sugihara, Hirosoada; Naka, Takehiko

CORPORATE SOURCE: Medicinal Chemistry Research Laboratories, Takeda Chemical Industries, Ltd., Osaka, 532-8686, Japan

SOURCE: Chemical Pharmaceutical Bulletin (2001), 49(3), 258-267

CODEN: CPBTAL; ISSN: 0009-2363


PUBLISHER: Pharmaceutical Society of Japan

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 135:5586

GI



I

AB To improve the *in vitro* and *in vivo* potency of our first low mol. weight GPIIb/IIIa antagonist methoxyoxethyloxopiperazinylacetic acid I (TMK-020), a series of substituted amidinobenzoylaminoacetyl methoxyoxethyloxopiperazinylacetic acids were synthesized through modifications of the tyrosine moiety of I and evaluated for their ability to inhibit *in vitro* ADP (ADP)-induced platelet aggregation through methylene-rich plasma (PRP). Among the compounds examined, amidinobenzoylaminoacetyl methoxyoxethyloxopiperazinylacetic acid I (R = 4-MeOC6H4CH3) showed the most potent antaggregatory activity with an IC50 value of 13 nM. Dose-dependent inhibition of *ex vivo* platelet aggregation was achieved with oral administration of I (R = 4-MeOC6H4CH3) (0.3-1.0 mg/kg) to guinea pigs. Complete inhibition was observed for up to 8 h, and 43% inhibition could still be observed 24 h after oral administration of 1.0 mg/kg. The long-lasting antiplatelet effect of I (R = 4-MeOC6H4CH3) suggests that I would be suitable for once-a-day dosing.

Structure-activity relationships (SAR) were examined in the series of the phenylalanine derivs. An increase in the electron d. around the 4-position of the Ph ring of the phenylalanine moiety led to an increase in the antiplatelet activity, suggesting the existence of a hydrophobic and electrostatic interaction site in addition to the ionic binding sites in the GPIIb/IIIa.

IT 340733-02-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological


L4 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)  
study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. of substituted amidinobenzoylaminoacetyl methoxyoxethyloxopiperazinylacetic acids as GPIIb and GPIIa antagonists for inhibition of platelet aggregation)

RN 340733-02-0 CAPLUS

CN 1,3-Piperazinediadic acid, 4-[(2S)-[4-(aminoiminomethyl)benzoyl]amino]p-henylacetyl]-2-oxo-,  $\alpha$ 3-methyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:900614 CAPLUS

DOCUMENT NUMBER: 134:56958

TITLE: Preparation of amino acid derivatives as serine protease inhibitors

INVENTOR(S): Liebeschuetz, John Walter; Lyons, Amanda Jane; Murray, Christopher William; Rimmer, Andrew David; Young, Stephen Clinton; Camp, Nicholas Paul; Jones, Stuart Donald; Morgan, Phillip John; Richards, Simon James; Wylie, William Alexander; Masters, John Joseph; Wiley, Michael Robert

PATENT ASSIGNEE(S): Eli Lilly and Company, USA; Protherics Molecular Design Limited

SOURCE: PCT Int. Appl., 261 pp.

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 13

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

WO 2000076971 A2 20001221 WO 2000-GB2302 20000613

WO 2000076971 A3 20010807

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TU, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2375920 AA 20001221 CA 2000-2375920 20000613

AU 2000054140 A5 20010102 AU 2000-54140 20000613

EP 1192132 A2 20020403 EP 2000-938916 20000613

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

JP 2003502314 T2 20030121 JP 2001-503831 20000613

CA 2411798 AA 20011220 CA 2001-2411798 20010612

CA 2411805 AA 20011220 CA 2001-2411805 20010612

WO 2001096296 A1 20011220 WO 2001-GB2541 20010612

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TZ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

WO 2001096303 A1 20011220 WO 2001-GB2551 20010612

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TZ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,

Habte

11/23/2004

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

BJ, CF, CG, CI, CH, GA, GN, GW, HL, MR, NE, SN, TD, TG  
WO 2001096323 A1 20011220 WO 2001-GB2553 20010612  
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, HD, RU, TJ, TH, RW: GH, GM, KE, LS, MW, HZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BG, CF, CG, CI, CH, GA, GN, GW, HL, MR, NE, SN, TD, TG  
WO 2001096304 A1 20011220 WO 2001-GB2572 20010612  
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, HD, RU, TJ, TH, RW: GR, GM, KE, LS, MW, HZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BG, CF, CG, CI, CH, GA, GN, GW, HL, MR, NE, SN, TD, TG  
EP 12899572 A1 20030312 EP 2001-936686 20010612  
EP 12899572 B1 20040908  
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, NO, MK, CY, AL, TR  
EP 12899580 A1 20030312 EP 2001-938386 20010612  
EP 12899580 B1 20040908  
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, NO, MK, CY, AL, TR  
EP 12899593 A1 20030312 EP 2001-938403 20010612  
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, NO, MK, CY, AL, TR  
EP 12899594 A1 20030312 EP 2001-940716 20010612  
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, NO, MK, CY, AL, TR  
BR 2001011451 A1 20030624 BR 2001-11451 20010612  
JP 2004053532 T2 20040205 JP 2002-510440 20010612  
JP 2004053547 T2 20040205 JP 2002-510466 20010612  
NZ 521896 A 20040730 NZ 2001-521896 20010612  
AT 275554 E 20040915 AT 2001-936686 20010612  
AT 275554 E 20040915 AT 2001-938386 20010612  
US 2002151724 A1 20021017 US 2002-30106 20020204  
US 6784182 B2 20040831  
US 2003078438 A1 20030424 US 2002-30189 20020204  
US 2003109706 A1 20030612 US 2002-30188 20020204  
ZA 2002009153 A 20040213 ZA 2002-9153 20021111  
NO 2002005665 A 20021125 NO 2002-5665 20021125  
US 2003216403 A1 20031120 US 2003-296245 20030514  
US 2004142963 A1 20040722 US 2004-754923 20040112  
US 2004176363 A1 20040909 US 2004-803157 20040318  
WO 2000-GB2302 W 20000613


PRIORITY APPLN. INFO.: GB 1999-13823 A 19990614  
US 1999-142064P P 19990702  
GB 1999-18741 A 19990809  
GB 1999-29553 A 19991214  
WO 2000-GB2302 W 20000613

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

313486-86-4P 313486-12-9P 313486-13-0P  
313486-14-1P 313486-16-3P 313486-18-5P  
313486-19-6P 313486-22-1P 313486-23-2P  
313486-24-3P 313486-25-4P 313486-26-5P  
313486-27-6P 313486-28-7P 313486-29-8P  
313486-30-1P 313486-31-2P 313486-32-3P  
313486-33-4P 313486-34-5P 313486-35-6P  
313486-36-7P 313486-50-5P 313486-51-6P  
313486-20-2P 313486-21-3P 313486-22-4P  
313486-23-5P 313486-24-6P 313486-25-7P  
313486-27-9P 313486-28-0P 313486-29-1P  
313486-30-4P 313486-58-6P 313486-59-7P  
313486-60-0P 313486-61-1P 313486-62-2P  
313486-63-3P 313486-64-4P 313486-65-5P  
313486-66-6P 313486-67-7P 313486-70-2P  
313486-71-3P 313486-72-4P 313486-73-5P  
313486-67-4P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (prepn. of amino acid derivs. as serine protease inhibitors)


RN 313486-84-9 CAPLUS  
CN Benzamide, 2-amino-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313486-85-0 CAPLUS  
CN Benzamide, 2-amino-4-chloro-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Habte

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

GB 2000-30303 A 20001213  
GB 2000-30304 A 20001213  
GB 2000-30305 A 20001213  
GB 2000-30306 A 20001213  
WO 2001-GB2541 W 20010612  
WO 2001-GB2551 W 20010612  
WO 2001-GB2553 W 20010612  
WO 2001-GB2566 W 20010612  
WO 2001-GB2572 W 20010612  
US 2002-30187 A1 20020204


OTHER SOURCE(S): MARPAT 134:56958  
AB Compds. R2-X-X-Y(Cy)-L-Lp(D)n [R2 represents a 5- or 6-membered aromatic carbon ring optionally interrupted by a N, O or S ring atom, optionally substituted at the 3 and/or 4 position or forms a fused system at these positions, which is an optionally substituted 5 or 6 membered carbocyclic or heterocyclic ring or substituted at the position alpha to X-X; X is a C, N, O or S atom or a CO, CR1a, C(R1a)2 or NR1a group, where R1a represents H, OH, alkoxy, alkyl, aminoalkyl, hydroxylalkyl, alkoxymethoxycarbonyl, alkoxycarbonyl, alkylaminocarbonyl, acyloxymethoxycarbonyl or alkylamino optionally substituted by OH, alkylamino, alkoxy, oxo, aryl or cycloalkyl; L is an organic linker group containing 1 to 5 backbone atoms selected from C, N and S, or a branched alkyl or cyclic group; Y is a N atom or a CR1b group (R1b defined as for R1a); Cy is an (un)substituted, (un)saturated, mono- or polycyclic, homo- or heterocyclic group; Lp is a lipophilic organic group; D is a hydrogen bond donor group (n = 0-2) were prepared for use as serine protease inhibitors. Compds. of the invention were found to significantly elongate the partial thromboplastin time (prothrombin time). Thus, 1-[3-amino-2-naphthoyl-D-phenylalanyl] 4'-bispeptidone was prepared and shown to double the prothrombin time at a concentration of 26 μM.

IT 313486-04-9P 313486-05-6P 313486-06-7P  
313486-07-2P 313486-08-3P 313486-09-4P  
313486-09-5P 313486-01-8P 313486-02-9P  
313486-02-0P 313486-04-1P 313486-05-2P  
313486-05-3P 313486-07-4P 313486-08-5P  
313486-09-6P 313486-07-0P 313486-08-3P  
313487-02-4P 313487-03-5P 313487-04-6P  
313487-05-7P 313487-06-8P 313487-07-9P  
313487-08-0P 313487-09-1P 313487-10-4P  
313487-11-5P 313487-12-6P 313487-13-7P  
313487-14-8P 313487-15-9P 313487-16-0P  
313487-17-1P 313487-18-2P 313487-19-3P  
313487-20-6P 313487-21-7P 313487-22-8P  
313487-23-9P 313487-24-0P 313487-25-1P  
313487-05-3P 313487-36-4P 313487-37-5P  
313487-38-6P 313487-39-7P 313487-40-0P  
313487-41-1P 313487-42-2P 313487-43-3P  
313487-44-4P 313487-45-5P 313487-46-6P  
313487-47-7P 313487-48-8P 313487-49-9P  
313487-50-2P 313487-51-3P 313487-52-4P  
313487-53-5P 313487-54-6P 313487-55-7P  
313487-56-8P 313487-57-9P 313487-67-1P  
313487-68-2P 313487-69-3P 313487-70-6P  
313487-71-7P 313487-72-8P 313487-73-9P  
313487-80-8P 313487-81-9P 313487-82-0P

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 313486-86-1 CAPLUS  
CN Benzamide, 2-amino-5-fluoro-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313486-87-2 CAPLUS  
CN Benzamide, 2-amino-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313486-88-3 CAPLUS  
CN Benzamide, 2-amino-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/23/2004

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 313486-89-4 CAPLUS  
 CN Benzamide, 2-amino-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-4-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313486-90-7 CAPLUS  
 CN Benzamide, 2-amino-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-5-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 313486-94-1 CAPLUS  
 CN Benzamide, N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313486-95-2 CAPLUS  
 CN Benzamide, 3-amino-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313486-96-3 CAPLUS  
 CN Benzamide, 4-amino-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Habte

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 313486-91-8 CAPLUS  
 CN Benzamide, 2-amino-5-cyano-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313486-92-9 CAPLUS  
 CN Benzamide, 2,5-diamino-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313486-93-0 CAPLUS  
 CN Benzamide, 2-amino-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-4,5-dimethoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 313486-97-4 CAPLUS  
 CN Benzamide, 3,4-diamino-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313486-98-5 CAPLUS  
 CN Benzamide, 3-chloro-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313486-99-6 CAPLUS  
 CN Benzamide, 4-chloro-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/23/2004

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 313487-00-2 CAPLUS  
 CN Benzamide, 3-amino-4-chloro-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313487-01-3 CAPLUS  
 CN Benzamide, 4-bromo-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313487-02-4 CAPLUS


L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)  
 CN Benzamide, N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-4-iodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313487-03-5 CAPLUS  
 CN Benzamide, 3-amino-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313487-04-6 CAPLUS  
 CN Benzamide, N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-4-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 313487-05-7 CAPLUS  
 CN Benzamide, 3-amino-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313487-06-8 CAPLUS  
 CN Benzamide, N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-3,4-dihydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313487-07-9 CAPLUS  
 CN 2-Naphthalenecarboxamide, N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Habte


L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.




RN 313487-08-0 CAPLUS  
 CN 2-Naphthalenecarboxamide, 3-amino-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313487-09-1 CAPLUS  
 CN 3-Thiophenecarboxamide, N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313487-10-4 CAPLUS  
 CN 2-Thiophenecarboxamide, N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

11/23/2004




RN 313487-11-5 CAPLUS  
CN 2-Thiophenecarboxamide, N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313487-12-6 CAPLUS  
CN 7-Isquinolinecarboxamide, N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313487-13-7 CAPLUS  
CN 3-Pyridinecarboxamide, N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313487-17-1 CAPLUS  
CN Benzamide, 4-ethenyl-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313487-18-2 CAPLUS  
CN Benzamide, 3-amino-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-4-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313487-19-3 CAPLUS  
CN Benzamide, N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-4-(methylthio)- (9CI) (CA INDEX NAME)

Habte




RN 313487-14-8 CAPLUS  
CN 1H-Indole-6-carboxamide, N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313487-15-9 CAPLUS  
CN Benzamide, N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-4-(methylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313487-16-0 CAPLUS  
CN Benzamide, 4-chloro-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313487-20-6 CAPLUS  
CN 1,3-Benzenedicarboxamide, N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313487-21-7 CAPLUS  
CN Benzamide, 4-bromo-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313487-22-8 CAPLUS  
CN Benzamide, 4-ethoxy-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

11/23/2004




RN 313487-23-9 CAPLUS  
CN 1H-Indole-5-carboxamide, N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313487-24-0 CAPLUS  
CN 1H-Benzimidazole-5-carboxamide, N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313487-34-2 CAPLUS  
CN Benzamide, 4-(ethylamino)-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)




RN 313487-35-3 CAPLUS  
CN Benzamide, N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-3-(methylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313487-36-4 CAPLUS  
CN Benzamide, 3-amino-4-chloro-N-[(1R)-2-[4-[2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313487-37-5 CAPLUS  
CN Benzamide, N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-

Absolute stereochemistry.




RN 313487-38-6 CAPLUS  
CN Benzamide, 4-(difluoromethoxy)-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313487-39-7 CAPLUS  
CN Benzamide, N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313487-40-0 CAPLUS  
CN 1H-Indole-3-carboxamide, N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Habte




RN 313487-41-1 CAPLUS  
CN Benzamide, 3-amino-4-chloro-N-[(1S)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313487-42-2 CAPLUS  
CN Benzoic acid, 2-[[[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]amino]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313487-43-3 CAPLUS  
CN Benzamide, 2-fluoro-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

11/23/2004


L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.




RN 313487-44-4 CAPLUS  
 CN 1H-Indole-6-carboxamide, 3-bromo-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313487-45-5 CAPLUS  
 CN 1H-Indole-6-carboxamide, 3-chloro-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 313487-49-9 CAPLUS  
 CN 1H-Indazole-6-carboxamide, N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313487-50-2 CAPLUS  
 CN Benzoic acid, 4-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]amino]carbonyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313487-51-3 CAPLUS  
 CN Benzamide, 4-(acetyloxy)-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-

Habte


L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)  
 RN 313487-46-6 CAPLUS  
 CN Benzamide, 2-cyano-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313487-47-7 CAPLUS  
 CN Benzamide, N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-2-(methylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313487-48-8 CAPLUS  
 CN Benzoic acid, 2-amino-4-[[[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]amino]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)  
 1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313487-52-4 CAPLUS  
 CN Pyrazinecarboxamide, N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313487-53-5 CAPLUS  
 CN 1,3-Benzodioxole-5-carboxamide, N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313487-54-6 CAPLUS  
 CN Benzamide, N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)


11/23/2004

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)  
Absolute stereochemistry.




RN 313487-55-7 CAPLUS  
CN 1H-Indole-6-carboxamide, 2,3-dichloro-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313487-56-8 CAPLUS  
CN 1H-Indole-6-carboxamide, 3-chloro-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 313487-69-3 CAPLUS  
CN Benzamide, 3-amino-N-[(1R)-2-[4-[4-(aminocarbonyl)-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-4-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313487-70-6 CAPLUS  
CN Benzamide, 3-amino-4-chloro-N-[(1R)-2-[4-[2-(methylsulfonyl)-4-nitrophenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313487-71-7 CAPLUS

Habte

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 313487-57-9 CAPLUS  
CN 1H-Indole-6-carboxamide, 3,3-dichloro-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313487-67-1 CAPLUS  
CN Benzamide, 3-amino-N-[(1R)-2-[4-[4-amino-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-4-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313487-68-2 CAPLUS  
CN Benzamide, 3-amino-N-[(1R)-2-[4-[4-amino-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)  
CN Benzamide, 3-amino-N-[(1R)-1-[4-aminophenyl]-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxoethyl]-4-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313487-72-8 CAPLUS  
CN Benzamide, 3-amino-N-[(1R)-1-[4-(aminocarbonyl)phenyl]-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxoethyl]-4-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313487-73-9 CAPLUS  
CN Benzamide, 3-amino-4-chloro-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-1-[4-[(methylamino)carbonyl]phenyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 313487-80-8 CAPLUS  
 CN Benzamide, 3-amino-4-chloro-N-[2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-(4-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 313487-81-9 CAPLUS  
 CN Benzamide, 3-amino-4-chloro-N-[2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-1-(1-methyl-4-piperidinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 313487-82-0 CAPLUS




RN 313487-86-4 CAPLUS  
 CN Benzamide, 4-chloro-N-[(1R)-2-oxo-1-phenyl-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313488-12-9 CAPLUS  
 CN Benzamide, 3-amino-N-[(1R)-1-[4-(aminocarbonyl)phenyl]-2-oxo-2-[4-(phenylmethyl)-1-piperazinyl]ethyl]-4-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313488-13-0 CAPLUS  
 CN Benzamide, 3-amino-N-[(1R)-1-[4-(aminocarbonyl)phenyl]-2-[4-(2-(methylthio)phenyl)-1-piperazinyl]-2-oxoethyl]-4-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313488-14-1 CAPLUS  
 CN Benzamide, 3-amino-N-[(1R)-1-[4-(aminocarbonyl)phenyl]-2-oxo-2-[4-(2-phenylethyl)-1-piperazinyl]ethyl]-4-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313488-16-3 CAPLUS  
 CN Benzamide, 3-amino-N-[(1R)-1-[4-(aminocarbonyl)phenyl]-2-[4-(2-ethylphenyl)-1-piperazinyl]-2-oxoethyl]-4-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313488-18-5 CAPLUS  
 CN Benzamide, 3-amino-4-chloro-N-[(1R)-1-cyclohexyl-2-[4-(4-fluoro-2-(methylsulfonyl)phenyl)-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 313488-19-6 CAPLUS  
CN Benzamide, 3-amino-4-chloro-N-[2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-1-(1-naphthalenyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 313488-22-1 CAPLUS  
CN Benzamide, 4-methoxy-N-[2-[4-[2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-(3-thienyl)ethyl]- (9CI) (CA INDEX NAME)




RN 313488-23-2 CAPLUS  
CN 1H-Indole-6-carboxamide, N-[2-[4-[2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-(3-thienyl)ethyl]- (9CI) (CA INDEX NAME)




RN 313488-24-3 CAPLUS  
CN Benzamide, N-[1-(3-fluorophenyl)-2-[4-[2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxoethyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 313488-25-4 CAPLUS  
CN 1H-Indole-6-carboxamide, N-[1-(3-fluorophenyl)-2-[4-[2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 313488-26-5 CAPLUS  
CN Benzamide, N-[1-(4-fluorophenyl)-2-[4-[2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxoethyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 313488-27-6 CAPLUS  
CN 1H-Indole-6-carboxamide, N-[1-(4-fluorophenyl)-2-[4-[2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 313488-28-7 CAPLUS  
CN Benzamide, N-[1-(2-chlorophenyl)-2-[4-[2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxoethyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 313488-29-8 CAPLUS  
CN 1H-Indole-6-carboxamide, N-[1-(2-chlorophenyl)-2-[4-[2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)



RN 313488-30-1 CAPLUS  
CN Benzamide, 4-methoxy-N-[1-(2-methylphenyl)-2-[4-[2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 313488-31-2 CAPLUS  
CN 1H-Indole-6-carboxamide, N-[1-(2-methylphenyl)-2-[4-[2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 313488-32-3 CAPLUS  
CN 1H-Indole-6-carboxamide, N-[1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-1-(2-fluorophenyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313488-33-4 CAPLUS  
CN Benzoic acid, 4-[(1R)-1-[(1H-indol-6-ylcarbonyl)amino]-2-[(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313488-34-5 CAPLUS  
CN 1H-Indole-6-carboxamide, N-[(1R)-2-[4-(4-hydroxyphenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313488-35-6 CAPLUS  
CN 1H-Indole-6-carboxamide, 3-chloro-N-[(1R)-2-[4-(4-hydroxyphenyl)-1-

Absolute stereochemistry.




RN 313488-36-7 CAPLUS  
CN Benzamide, 4-methoxy-N-[(1R)-1-(4-methoxyphenyl)-2-[4-(2-methylsulfonyl)phenyl]-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313488-50-5 CAPLUS  
CN Benzamide, N-[(1R)-1-(4-hydroxyphenyl)-2-[4-(2-methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313488-51-6 CAPLUS  
CN 1H-Indole-6-carboxamide, N-[(1R)-1-(4-hydroxyphenyl)-2-[4-(2-methylsulfonyl)phenyl]-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313489-20-2 CAPLUS  
CN Benzamide, 4-methoxy-N-[(1R)-2-oxo-1-phenyl-2-(4-(4-piperidinylmethyl)-1-piperazinyl)ethyl]-, trifluoroacetate (2:5) (9CI) (CA INDEX NAME)

CM 1

CRN 313489-19-9  
CMF C26 H34 N4 O3

Absolute stereochemistry.




CM 2

Habte



RN 313489-21-3 CAPLUS  
CN Benzamide, 4-methoxy-N-[(1R)-2-[4-(1-methyl-4-piperidinyl)methyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



• 3 HCl

RN 313489-22-4 CAPLUS  
CN Benzamide, 4-methoxy-N-[(1R)-2-[4-[(1-(1-methylsulfonyl)-4-piperidinyl)methyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




• 3 HCl

RN 313489-23-5 CAPLUS  
CN Benzamide, 4-methoxy-N-[(1R)-2-oxo-1-phenyl-2-[4-(3-pyridinyl)propyl]-1-piperazinyl]ethyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/23/2004



● x HCl

RN 313489-24-6 CAPLUS  
 CN Benzanide, 4-methoxy-N-[(1R)-2-oxo-1-phenyl-2-[4-[3-(4-pyridinyl)propyl]-1-piperazinyl]ethyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● x HCl

RN 313489-25-7 CAPLUS  
 CN Benzanide, N-[(1R)-2-[4-(2-cyclopentylethyl)-1-piperazinyl]-2-oxo-1-phenylethyl]-4-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● x HCl


L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)  
 RN 313489-28-0 CAPLUS  
 CN Benzanide, 4-methoxy-N-[(1R)-2-oxo-1-phenyl-2-[4-[2-(4-pyridinyl)ethyl]-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313489-29-1 CAPLUS  
 CN Benzanide, 4-methoxy-N-[(1R)-2-[4-(1-methyl-3-pyrrolidinyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313489-30-4 CAPLUS  
 CN Benzanide, 4-methoxy-N-[(1R)-2-[4-[1-(1-methylethyl)-3-pyrrolidinyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Habte



● HCl


RN 313489-27-9 CAPLUS  
 CN Benzanide, 4-methoxy-N-[(1R)-2-oxo-1-phenyl-2-[4-(3-pyrrolidinyl)-1-piperazinyl]ethyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 313489-26-8

CNF C24 H30 N4 O3

Absolute stereochemistry.



CM 2


CRN 76-05-1

CNF C2 H F3 O2




RN 313489-58-6 CAPLUS  
 CN Benzanide, 4-methoxy-N-[(1R)-2-oxo-1-phenyl-2-[4-(2-pyridinylmethyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313489-59-7 CAPLUS  
 CN Benzanide, 4-methoxy-N-[(1R)-2-oxo-1-phenyl-2-[4-(3-pyridinylmethyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313489-60-0 CAPLUS  
 CN Benzanide, 4-methoxy-N-[(1R)-2-oxo-1-phenyl-2-[4-(4-pyridinylmethyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313489-61-1 CAPLUS  
 CN Benzanide, 4-methoxy-N-[(1R)-2-oxo-1-phenyl-2-[4-(2-phenylethyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

11/23/2004




RN 313489-62-2 CAPLUS  
 CN Benzamide, N-[(1R)-2-[4-(1-ethylpropyl)-1-piperazinyl]-2-oxo-1-phenylethyl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313489-63-3 CAPLUS  
 CN Benzamide, N-[(1R)-2-(4-cyclopentyl-1-piperazinyl)-2-oxo-1-phenylethyl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313489-64-4 CAPLUS  
 CN Benzamide, 4-methoxy-N-[(1R)-2-oxo-1-phenyl-2-[4-(tetrahydro-2H-thiopyran-4-yl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313489-70-2 CAPLUS  
 CN Benzamide, 4-methoxy-N-[(1R)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 313489-71-3 CAPLUS  
 CN 1H-Indole-6-carboxamide, N-[(1R)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 313489-72-4 CAPLUS  
 CN 1H-Indole-6-carboxamide, 3-methyl-N-[(1R)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313489-65-5 CAPLUS  
 CN Benzamide, N-[(1R)-2-[4-(2,3-dihydro-1H-inden-2-yl)-1-piperazinyl]-2-oxo-1-phenylethyl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313489-66-6 CAPLUS  
 CN Benzamide, 4-methoxy-N-[(1R)-2-oxo-1-phenyl-2-[4-(phenylmethyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313489-67-7 CAPLUS  
 CN Benzamide, N-[(1R)-2-[4-(cyclohexylmethyl)-1-piperazinyl]-2-oxo-1-phenylethyl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313489-73-5 CAPLUS  
 CN 1H-Indole-6-carboxamide, 3-chloro-N-[(1R)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313690-67-4 CAPLUS  
 CN Benzamide, 4-methoxy-N-[(1R)-2-[4-(4-methylcyclohexyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 313490-70-9P 313490-72-1P 313490-73-2P  
 RN: RCT (Reactant); SPP (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of amino acid derivs. as serine protease inhibitors)

RN 313490-70-9 CAPLUS  
 1-Piperazinecarboxylic acid, 4-[(2R)-{4-(methoxybenzoyl)amino}phenylacetyl]

11/23/2004

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)  
1-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

RN 313490-72-1 CAPLUS  
CN Benzanide, 4-methoxy-N-[(1R)-2-oxo-1-phenyl-2-(1-piperazinyl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313490-71-0  
CNF C20 H23 N3 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1  
CNF C2 H F3 O2RN 313490-73-2 CAPLUS  
CN 1-Piperidinecarboxylic acid, 4-[[4-[(2R)-[(4-methoxybenzoyl)aminophenylacetyl]-1-piperazinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)  
ACCESSION NUMBER: 20001900613 CAPLUS  
DOCUMENT NUMBER: 134:56957  
TITLE: Preparation of amino acid derivatives as serine protease inhibitors  
INVENTOR(S): Liebeschuetz, John Walter; Lyons, Amanda Jane; Murray, Christopher William; Rimmer, Andrew David; Young, Stephen Clinton; Camp, Nicholas Paul; Jones, Stuart Donald; Morgan, Phillip John; Richards, Simon James; Wylie, William Alexander; Lively, Sarah Elizabeth; Harrison, Martin James; Waszkowycz, Bohdan; Masters, John Joseph; Wiley, Michael John  
PATENT ASSIGNEE(S): Eli Lilly and Company, USA; Protherics Molecular Design Limited  
SOURCE: PCT Int. Appl., 350 pp.  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 13  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000076970	A2	20001221	WO 2000-GB2296	20000613
WO 2000076970	A3	20010719		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KE, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2383008	AA	20001221	CA 2000-2383008	20000613
EP 1192135	A2	20020403	EP 2000-938912	20000613
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2003216403	A1	20031120	US 2003-296245	20030514
PRIORITY APPLN. INFO.:				
GB 1999-13823	A		19990614	
US 1999-142064P	P		19990702	
GB 1999-18741	A		19990809	
GB 1999-29552	A		19991214	
GB 1999-29553	A		19991214	
WO 2000-GB2296	W		20000613	
WO 2001-GB2566	W		20010612	

OTHER SOURCE(S): MARPAT 134:56957


AB Compds. R2-X-Y(Cy)-L-Lp(D)n [R2 represents a 5- or 6-membered aromatic carbon ring optionally interrupted by a N, O or S ring atom, optionally substituted at the 3 and/or 4 position or forms a fused ring system at these positions, which is an optionally substituted 5 or 6 membered carbocyclic or heterocyclic ring; X is a C, N, O or S atom or a CO, CR1a, CR1a2 or NR1a group, where R1a represents H, OH, alkoxy, alkyl, aminoalkyl, hydroxylalkyl, alkoxylalkyl, alkoxycarbonyl, alkylaminocarbonyl, alkoxy carbonyl, acyloxy methoxycarbonyl or alkylamino optionally substituted by OH, alkylamino, alkoxy, oxo, aryl or cycloalkyl; L is an organic linker group containing 1 to 5 backbone atoms selected from C, N, O and

S, or a branched alkyl or cyclic group; Y is a N atom or a CR1b group (R1b defined as for R1a); Cy is an (un)substituted, (un)saturated, mono- or


Habte

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


Absolute stereochemistry.

RN 313490-74-3 CAPLUS  
CN Benzanide, N-[(1R)-2-[4-(2-cyclopentylethyl)-1-piperazinyl]-2-oxo-1-phenylethyl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 313490-75-4 CAPLUS  
CN 1-Pyrrolidinecarboxylic acid, 3-[4-[(2R)-[(4-methoxybenzoyl)aminophenylacetyl]-1-piperazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)  
polycyclic, homo- or heterocyclic group; Lp is a lipophilic org. group; D is a hydrogen bond donor group; n ~ 0-2 were prep'd. for use as serine protease inhibitors. Compds. of the invention were found to significantly elongate the partial thromboplastin time (prothrombin time). Thus, 1-(3-amino-2-naphthoyl-D-phenylglycyl)-4,4'-bis(piperidine was prep'd. and shown to double the prothrombin time at a concn. of 26  $\mu$ M.IT 313486-04-9P 313486-85-0P 313486-86-1P  
313486-87-2P 313486-88-3P 313486-89-4P  
313486-90-7P 313486-91-8P 313486-92-9P  
313486-93-0P 313486-94-1P 313486-95-2P  
313486-96-3P 313486-97-4P 313486-98-5P  
313486-99-6P 313487-00-2P 313487-01-3P  
313487-02-4P 313487-03-5P 313487-04-6P  
313487-05-7P 313487-06-8P 313487-07-9P  
313487-08-0P 313487-09-1P 313487-10-4P  
313487-11-5P 313487-12-6P 313487-13-7P  
313487-14-8P 313487-15-9P 313487-16-0P  
313487-17-1P 313487-18-2P 313487-19-3P  
313487-20-6P 313487-21-7P 313487-22-8P  
313487-23-9P 313487-24-0P 313487-34-2P  
313487-35-3P 313487-36-4P 313487-37-5P  
313487-38-6P 313487-39-7P 313487-40-0P  
313487-41-1P 313487-42-2P 313487-43-3P  
313487-44-4P 313487-45-5P 313487-46-6P  
313487-47-7P 313487-48-8P 313487-49-9P  
313487-50-2P 313487-51-3P 313487-52-4P  
313487-53-5P 313487-54-6P 313487-55-7P  
313487-56-8P 313487-57-9P 313487-67-1P  
313487-68-2P 313487-69-3P 313487-70-6P  
313487-71-7P 313487-72-8P 313487-73-9P  
313487-80-9P 313487-81-0P 313487-82-1P  
313487-86-4P 313488-12-9P 313488-13-0P  
313488-14-1P 313489-16-3P 313489-18-5P  
313489-19-6P 313489-22-1P 313489-23-2P  
313489-24-3P 313489-25-4P 313489-26-5P  
313489-27-6P 313489-28-7P 313489-29-8P  
313489-30-1P 313489-31-2P 313489-32-3P  
313489-33-4P 313489-34-5P 313489-35-6P  
313489-36-7P 313489-50-5P 313489-51-6P  
313489-20-2P 313489-21-3P 313489-22-4P  
313489-23-5P 313489-24-6P 313489-25-7P  
313489-27-9P 313489-28-0P 313489-29-1P  
313489-30-4P 313489-58-6P 313489-59-7P  
313489-60-0P 313489-61-1P 313489-62-2P  
313489-63-3P 313489-64-4P 313489-65-5P  
313489-66-6P 313489-67-7P 313489-70-2P  
313489-71-3P 313489-72-4P 313489-73-5P  
313690-67-4P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of amino acid derivs. as serine protease inhibitors)RN 313486-84-9 CAPLUS  
CN Benzanide, 2-amino-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

11/23/2004





RN 313486-85-0 CAPLUS  
 CN Benzamide, 2-amino-4-chloro-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313486-86-1 CAPLUS  
 CN Benzamide, 2-amino-5-fluoro-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313486-90-7 CAPLUS  
 CN Benzamide, 2-amino-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-5-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313486-91-8 CAPLUS  
 CN Benzamide, 2-amino-5-cyano-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313486-92-9 CAPLUS  
 CN Benzamide, 2,5-diamino-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Habte


L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)  
 RN 313486-87-2 CAPLUS  
 CN Benzamide, 2-amino-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313486-88-3 CAPLUS  
 CN Benzamide, 2-amino-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313486-89-4 CAPLUS  
 CN Benzamide, 2-amino-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-4-nitro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 313486-93-0 CAPLUS  
 CN Benzamide, 2-amino-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-4,5-dimethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313486-94-1 CAPLUS  
 CN Benzamide, N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313486-95-2 CAPLUS

11/23/2004


L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)  
 CN Benzamide, 3-amino-N-[(1R)-2-[4-(4-fluoro-2-(methylsulfonyl)phenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313486-96-3 CAPLUS  
 CN Benzamide, 3-amino-N-[(1R)-2-[4-(4-fluoro-2-(methylsulfonyl)phenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313486-97-4 CAPLUS  
 CN Benzamide, 3,4-diamino-N-[(1R)-2-[4-(4-fluoro-2-(methylsulfonyl)phenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)  
 CN Benzamide, 3-amino-N-[(1R)-2-[4-(4-fluoro-2-(methylsulfonyl)phenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313487-01-3 CAPLUS  
 CN Benzamide, 4-bromo-N-[(1R)-2-[4-(4-fluoro-2-(methylsulfonyl)phenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313487-02-4 CAPLUS  
 CN Benzamide, N-[(1R)-2-[4-(4-fluoro-2-(methylsulfonyl)phenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]-4-iodo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313487-03-5 CAPLUS


Habte

L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 313486-98-5 CAPLUS  
 CN Benzamide, 3-chloro-N-[(1R)-2-[4-(4-fluoro-2-(methylsulfonyl)phenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313486-99-6 CAPLUS  
 CN Benzamide, 4-chloro-N-[(1R)-2-[4-(4-fluoro-2-(methylsulfonyl)phenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313487-00-2 CAPLUS  
 CN Benzamide, 3-amino-4-chloro-N-[(1R)-2-[4-(4-fluoro-2-


L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)  
 CN Benzamide, 3-amino-N-[(1R)-2-[4-(4-fluoro-2-(methylsulfonyl)phenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313487-04-6 CAPLUS  
 CN Benzamide, N-[(1R)-2-[4-(4-fluoro-2-(methylsulfonyl)phenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313487-05-7 CAPLUS  
 CN Benzamide, 3-amino-N-[(1R)-2-[4-(4-fluoro-2-(methylsulfonyl)phenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.









RN 313487-18-2 CAPLUS  
CN Benzamide, 3-amino-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-4-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313487-19-3 CAPLUS  
CN Benzamide, N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-4-(methylthio)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313487-20-6 CAPLUS  
CN 1,3-Benzenedicarboxamide, N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)  
RN 313487-23-9 CAPLUS  
CN 1H-Indole-5-carboxamide, N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313487-24-0 CAPLUS  
CN 1H-Benzimidazole-5-carboxamide, N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313487-34-2 CAPLUS  
CN Benzamide, 4-(ethylamino)-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313487-35-3 CAPLUS  
CN Benzamide, N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-3-(methylamino)- (9CI) (CA INDEX NAME)


Habte

Absolute stereochemistry.




RN 313487-21-7 CAPLUS  
CN Benzamide, 4-bromo-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313487-22-8 CAPLUS  
CN Benzamide, 4-ethoxy-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Absolute stereochemistry.




RN 313487-36-4 CAPLUS  
CN Benzamide, 3-amino-4-chloro-N-[(1R)-2-[4-[2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313487-37-5 CAPLUS  
CN Benzamide, N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313487-38-6 CAPLUS  
CN Benzamide, 4-(difluoromethoxy)-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)  
Absolute stereochemistry.




RN 313487-39-7 CAPLUS  
CN Benzamide, N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313487-40-0 CAPLUS  
CN 1H-Indole-3-carboxamide, N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313487-41-1 CAPLUS  
CN Benzamide, 3-amino-4-chloro-N-[(1S)-2-[4-[4-fluoro-2-

L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 313487-44-4 CAPLUS  
CN 1H-Indole-6-carboxamide, 3-bromo-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313487-45-5 CAPLUS  
CN 1H-Indole-6-carboxamide, 3-chloro-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313487-46-6 CAPLUS  
CN Benzamide, 2-cyano-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



Habte


L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)  
(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313487-42-2 CAPLUS  
CN Benzoic acid, 2-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]amino]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313487-43-3 CAPLUS  
CN Benzamide, 2-fluoro-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)  
RN 313487-47-7 CAPLUS  
CN Benzamide, N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-2-(methylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313487-48-8 CAPLUS  
CN Benzoic acid, 2-amino-4-[[[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]amino]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313487-49-9 CAPLUS  
CN 1H-Indazole-6-carboxamide, N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313487-50-2 CAPLUS

11/23/2004


L4 ANSWER 12 OF 16 CAPIUS COPYRIGHT 2004 ACS on STN (Continued)  
 CN Benzoic acid, 4-[[[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313487-51-3 CAPIUS  
 CN Benzamide, 4-(acetoxy)-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313487-52-4 CAPIUS  
 CN Pyrazinecarboxamide, N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 16 CAPIUS COPYRIGHT 2004 ACS on STN (Continued)




RN 313487-53-5 CAPIUS  
 CN 1,3-Benzodioxole-5-carboxamide, N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313487-54-6 CAPIUS  
 CN Benzamide, N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313487-55-7 CAPIUS  
 CN 1H-Indole-6-carboxamide, 2,3-dichloro-N-[(1R)-2-[4-[4-fluoro-2-


L4 ANSWER 12 OF 16 CAPIUS COPYRIGHT 2004 ACS on STN (Continued)  
 (methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313487-56-8 CAPIUS  
 CN 1H-Indole-6-carboxamide, 3-chloro-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313487-57-9 CAPIUS  
 CN 1H-Indole-6-carboxamide, 3,3-dichloro-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 12 OF 16 CAPIUS COPYRIGHT 2004 ACS on STN (Continued)  
 RN 313487-67-1 CAPIUS  
 CN Benzamide, 3-amino-N-[(1R)-2-[4-[4-amino-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-4-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313487-68-2 CAPIUS  
 CN Benzamide, 3-amino-N-[(1R)-2-[4-[4-amino-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313487-69-3 CAPIUS  
 CN Benzamide, 3-amino-N-[(1R)-2-[4-[4-(aminocarbonyl)-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-4-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313487-70-6 CAPLUS  
 CN Benzamide, 3-amino-4-chloro-N-[(1R)-2-[2-(methylsulfonyl)-4-nitrophenyl]-1-piperazinyl]-2-oxo-1-phenylethyl- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.




RN 313487-71-7 CAPLUS  
 CN Benzamide, 3-amino-N-[(1R)-1-(4-aminophenyl)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxoethyl]-4-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313487-80-8 CAPLUS  
 CN Benzamide, 3-amino-4-chloro-N-[2-[4-(4-fluoro-2-(methylsulfonyl)phenyl)-1-piperazinyl]-2-oxo-1-(4-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 313487-81-9 CAPLUS  
 CN Benzamide, 3-amino-4-chloro-N-[2-[4-(4-fluoro-2-(methylsulfonyl)phenyl)-1-piperazinyl]-1-(1-methyl-4-piperidinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 313487-82-0 CAPLUS  
 CN Benzamide, 3-amino-4-chloro-N-[2-[4-(4-fluoro-2-(methylsulfonyl)phenyl)-1-piperazinyl]-2-oxo-1-[1-(trifluoroacetyl)-4-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Habte




RN 313487-72-8 CAPLUS  
 CN Benzamide, 3-amino-N-[(1R)-1-[4-(aminocarbonyl)phenyl]-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxoethyl]-4-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313487-73-9 CAPLUS  
 CN Benzamide, 3-amino-4-chloro-N-[(1R)-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-1-[4-(methylamino)carbonyl]phenyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313487-86-4 CAPLUS  
 CN Benzamide, 4-chloro-N-[(1R)-2-oxo-1-phenyl-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313488-12-9 CAPLUS  
 CN Benzamide, 3-amino-N-[(1R)-1-[4-(aminocarbonyl)phenyl]-2-oxo-2-[4-(phenylmethyl)-1-piperazinyl]ethyl]-4-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313488-13-0 CAPLUS  
 11/23/2004


L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)  
 CN Benzamide, 3-amino-N-[(1R)-1-[4-(aminocarbonyl)phenyl]-2-[4-(2-methylthio)phenyl]-1-piperazinyl]-2-oxoethyl]-4-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313488-14-1 CAPLUS  
 CN Benzamide, 3-amino-N-[(1R)-1-[4-(aminocarbonyl)phenyl]-2-oxo-2-[4-(2-phenylethyl)-1-piperazinyl]ethyl]-4-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313488-16-3 CAPLUS  
 CN Benzamide, 3-amino-N-[(1R)-1-[4-(aminocarbonyl)phenyl]-2-[4-(2-ethylphenyl)-1-piperazinyl]-2-oxoethyl]-4-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 313488-18-5 CAPLUS  
 CN Benzamide, 3-amino-4-chloro-N-[(1R)-1-cyclohexyl-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313488-19-6 CAPLUS  
 CN Benzamide, 3-amino-4-chloro-N-[2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-1-(1-naphthalenyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 313488-22-1 CAPLUS  
 CN Benzamide, 4-methoxy-N-[2-[4-(2-(methylsulfonyl)phenyl)-1-piperazinyl]-2-oxo-1-(3-thienyl)ethyl]- (9CI) (CA INDEX NAME)




RN 313488-23-2 CAPLUS  
 CN 1H-Indole-6-carboxamide, N-[2-[4-[2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxo-1-(3-thienyl)ethyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 313488-24-3 CAPLUS  
 CN Benzamide, N-[1-(3-fluorophenyl)-2-[4-(2-(methylsulfonyl)phenyl)-1-piperazinyl]-2-oxoethyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 313488-25-4 CAPLUS  
 CN 1H-Indole-6-carboxamide, N-[1-(3-fluorophenyl)-2-[4-(2-(methylsulfonyl)phenyl)-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 313488-26-5 CAPLUS  
 CN Benzamide, N-[1-(4-fluorophenyl)-2-[4-(2-(methylsulfonyl)phenyl)-1-piperazinyl]-2-oxoethyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 313488-27-6 CAPLUS  
 CN 1H-Indole-6-carboxamide, N-[1-(4-fluorophenyl)-2-[4-(2-(methylsulfonyl)phenyl)-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 313488-28-7 CAPLUS  
 CN Benzamide, N-[1-(2-chlorophenyl)-2-[4-[2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxoethyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 313488-29-8 CAPLUS  
 CN 1H-Indole-6-carboxamide, N-[1-(2-chlorophenyl)-2-[4-[2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)



RN 313488-30-1 CAPLUS  
 CN Benzamide, 4-methoxy-N-[1-(2-methylphenyl)-2-[4-[2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 313488-31-2 CAPLUS  
 CN 1H-Indole-6-carboxamide, N-[1-(2-methylphenyl)-2-[4-[2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 313488-32-3 CAPLUS  
 CN 1H-Indole-6-carboxamide, N-[1R]-2-[4-[4-fluoro-2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313488-33-4 CAPLUS  
 CN Benzoic acid, 4-[(1R)-1-[(1H-indol-6-ylcarbonyl)amino]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313488-34-5 CAPLUS  
 CN 1H-Indole-6-carboxamide, N-[(1R)-2-[4-(4-hydroxyphenyl)-1-piperazinyl]-2-oxo-1-phenethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313488-35-6 CAPLUS  
 CN 1H-Indole-6-carboxamide, 3-chloro-N-[(1R)-2-[4-(4-hydroxyphenyl)-1-piperazinyl]-2-oxo-1-phenethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313488-36-7 CAPLUS  
 CN Benzamide, 4-methoxy-N-[(1R)-1-(4-methoxyphenyl)-2-[4-[2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Habte




RN 313488-50-5 CAPLUS  
 CN Benzamide, N-[(1R)-1-(4-hydroxyphenyl)-2-[4-[2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxoethyl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313488-51-6 CAPLUS  
 CN 1H-Indole-6-carboxamide, N-[(1R)-1-(4-hydroxyphenyl)-2-[4-[2-(methylsulfonyl)phenyl]-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313489-20-2 CAPLUS  
 CN Benzamide, 4-methoxy-N-[(1R)-2-oxo-1-phenyl-2-[4-(4-piperidinylmethyl)-1-


11/23/2004

L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)  
 CN Benzanide, N-[1-(3-piperazinyl)ethyl]-, trifluoroacetate (2:5) (9CI) (CA INDEX NAME)

CM 1

CRN 313489-19-9  
 CMF C26 H34 N4 O3

Absolute stereochemistry.




CM 2

CRN 76-05-1  
 CMF C2 H F3 O2



RN 313489-21-3 CAPLUS  
 CN Benzanide, 4-methoxy-N-[1R)-2-[4-[(1-methyl-4-piperidinyl)methyl]-1-piperazinyl]-2-oxo-1-phenylethyl-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 313489-22-4 CAPLUS  
 CN Benzanide, 4-methoxy-N-[1R)-2-[4-[(1-(1-methylethyl)-4-piperidinyl)methyl]-1-piperazinyl]-2-oxo-1-phenylethyl-, trihydrochloride


L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



●x HCl

RN 313489-25-7 CAPLUS  
 CN Benzanide, N-[1R)-2-[4-(2-cyclopentylethyl)-1-piperazinyl]-2-oxo-1-phenylethyl]-4-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 313489-27-9 CAPLUS  
 CN Benzanide, 4-methoxy-N-[1R)-2-oxo-1-phenyl-2-(4-(3-pyrrolidinyl)-1-piperazinyl)ethyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 313489-26-8  
 CMF C24 H30 N4 O3

Absolute stereochemistry.

L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)  
 CN Benzanide, 4-methoxy-N-[1R)-2-oxo-1-phenyl-2-[4-(3-pyridinyl)propyl]-1-piperazinyl]ethyl-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 3 HCl

RN 313489-23-5 CAPLUS  
 CN Benzanide, 4-methoxy-N-[1R)-2-oxo-1-phenyl-2-[4-(3-pyridinyl)propyl]-1-piperazinyl]ethyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 313489-24-6 CAPLUS  
 CN Benzanide, 4-methoxy-N-[1R)-2-oxo-1-phenyl-2-[4-(4-pyridinyl)propyl]-1-piperazinyl]ethyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




CM 2

CRN 76-05-1  
 CMF C2 H F3 O2



RN 313489-28-0 CAPLUS  
 CN Benzanide, 4-methoxy-N-[1R)-2-oxo-1-phenyl-2-[4-(2-pyridinyl)ethyl]-1-piperazinyl]ethyl-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313489-29-1 CAPLUS  
 CN Benzanide, 4-methoxy-N-[1R)-2-[4-(1-methyl-3-pyrrolidinyl)-1-piperazinyl]-2-oxo-1-phenylethyl-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 313489-30-4 CAPLUS  
 CN Benzamide, 4-methoxy-N-[(1R)-2-[4-[(1-methylethyl)-3-pyrrolidinyl]-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313489-58-6 CAPLUS  
 CN Benzamide, 4-methoxy-N-[(1R)-2-oxo-1-phenyl-2-[4-(2-pyridinylmethyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313489-59-7 CAPLUS  
 CN Benzamide, 4-methoxy-N-[(1R)-2-oxo-1-phenyl-2-[4-(3-pyridinylmethyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.




RN 313489-60-0 CAPLUS  
 CN Benzamide, 4-methoxy-N-[(1R)-2-oxo-1-phenyl-2-[4-(4-pyridinylmethyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313489-61-1 CAPLUS  
 CN Benzamide, 4-methoxy-N-[(1R)-2-oxo-1-phenyl-2-[4-(2-phenylethyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313489-62-2 CAPLUS  
 CN Benzamide, N-[(1R)-2-[4-(1-ethylpropyl)-1-piperazinyl]-2-oxo-1-phenylethyl]-4-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 313489-63-3 CAPLUS  
 CN Benzamide, N-[(1R)-2-(4-cyclopentyl-1-piperazinyl)-2-oxo-1-phenylethyl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313489-64-4 CAPLUS  
 CN Benzamide, 4-methoxy-N-[(1R)-2-oxo-1-phenyl-2-[4-(tetrahydro-2H-thiopyran-4-yl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313489-65-5 CAPLUS  
 CN Benzamide, N-[(1R)-2-[4-(2,3-dihydro-1H-inden-2-yl)-1-piperazinyl]-2-oxo-1-phenylethyl]-4-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 313489-66-6 CAPLUS  
 CN Benzamide, 4-methoxy-N-[(1R)-2-oxo-1-phenyl-2-[4-(phenylmethyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313489-67-7 CAPLUS  
 CN Benzamide, N-[(1R)-2-[4-(cyclohexylmethyl)-1-piperazinyl]-2-oxo-1-phenylethyl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313489-70-2 CAPLUS  
 CN Benzamide, 4-methoxy-N-[(1R)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 313489-71-3 CAPLUS  
 CN 1H-Indole-6-carboxamide, N-[(1R)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 313489-72-4 CAPLUS  
 CN 1H-Indole-6-carboxamide, 3-methyl-N-[(1R)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313489-73-5 CAPLUS  
 CN 1H-Indole-6-carboxamide, 3-chloro-N-[(1R)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)




RN 313490-72-1 CAPLUS  
 CN Benzamide, 4-methoxy-N-[(1R)-2-oxo-1-phenyl-2-(1-piperazinyl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313490-71-0  
 CMF C20 H23 N3 O3

Absolute stereochemistry.




CM 2

CRN 76-05-1  
 CMF C2 H F3 O2




RN 313490-73-2 CAPLUS  
 CN 1-Piperidinecarboxylic acid, 4-[(4-[(2R)-[(4-methoxybenzoyl)amino]phenylacetyl]-1-piperazinyl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313690-67-4 CAPLUS  
 CN Benzamide, 4-methoxy-N-[(1R)-2-[4-(4-methylcyclohexyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 313490-70-9P 313490-72-1P 313490-73-2P  
 313490-74-3P 313490-75-4P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent); (preparation of amino acid derivs. as serine protease inhibitors)  
 RN 313490-70-9 CAPLUS  
 CN 1-Piperazinecarboxylic acid, 4-[(2R)-[(4-methoxybenzoyl)amino]phenylacetyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313490-74-3 CAPLUS  
 CN Benzamide, N-[(1R)-2-[4-(2-cyclopentylethyl)-1-piperazinyl]-2-oxo-1-phenylethyl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313490-75-4 CAPLUS  
 CN 1-Pyrrolidinecarboxylic acid, 3-[(2R)-[(4-methoxybenzoyl)amino]phenylacetyl]-1-piperazinyl-2-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN  
 ACCESSION NUMBER: 1999-184269 CAPLUS  
 DOCUMENT NUMBER: 130:237884  
 TITLE: Preparation of meta-benzamidine derivatives of amino acids or dipeptides as serine protease inhibitors  
 INVENTOR(S): Liebeschuetz, John Walter; Wylie, William Alexander; Waszkowycz, Bohdan; Murray, Christopher William; Rimmer, Andrew David; Welsh, Pauline Mary; Jones, Stuart Donald; Roscoe, Jonathan Michael Ernest; Young, Stephen Clinton; Morgan, Phillip John  
 PATENT ASSIGNEE(S): Proteus Molecular Design Ltd., UK  
 SOURCE: PCT Int. Appl., 110 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 13  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9911658	A1	19990311	WO 1998-0B2605	19980828
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, ES, ET, FI, GB, GH, GM, HR, IL, IS, JP, KE, KG, KP, KW, KZ, LC, LR, LS, LT, LV, MD, MG, MK, MN, MW, HX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, TJ, TM, TT, UN, US, UZ, VZ, YU, ZW	AM: AZ, BY, KG, KZ, MD, RO, TJ, TM	ES: FI, FR, GH, KZ, LS, MW, SD, SZ, UC, ZW	AT: BE, CH, CY, DE, DK, ES, FI, FR, GH, KZ, LS, MW, SD, SZ, UC, ZW	IT: BE, CH, CY, DE, DK, ES, FI, FR, GH, KZ, LS, MW, SD, SZ, UC, ZW
US 9888757	A1	19990322	AU 1998-89757	19980828
EP 1009758	A1	20000621	EP 1998-940430	19980828
R: DE, FR, GB, IT				
US 2002055522	A1	20020509	US 2001-988082	20011119
US 6740682	B2	20040525		
US 2003216403	A1	20031120	US 2003-296245	20030514
US 2004143018	A1	20040722	US 2004-752568	20040108
GB 1997-18392	A	19970829		
GB 1998-3173	A	19980213		
WO 1998-0B2605	W	19980828		
GB 1999-13923	A	19990614		
US 1999-142064P	P	19990702		
US 2000-485678	A2	20000225		
WO 2000-0B2291	A2	20000613		
WO 2001-0B2566	W	20010612		
US 2001-988082	A1	20011119		

PRIORITY APPLN. INFO.: OTHER SOURCE(S): HARPAT 130:237884  
 GI

L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




AB Title compds. I (R1, R2 = H, OH, alkoxy, alkyl, aminoalkyl, hydroxylalkyl, alkoxylalkyl, alkoxycarbonyl, acyloxymethoxycarbonyl or alkylamino optionally substituted by hydroxy, alkylamino, alkoxy, oxo, carbonyl, cycloalkyl; R3 = H, R2 as above, halo, cyano, nitro, chloro, alkylthio, alkylsulfonyl, alkylsulfonylphenyl, alkylsulfonamido, alkylaminoalkylthio, haloalkoxy, haloalkyl, (poly)cyclic, (hetero)cyclic group optionally substituted by groups R3 or Ph optionally substituted by R3; Lp = lipophilic alkyl, heterocyclic, alkenyl, alkaryl, (poly)cycloalkyl, cycloalkenyl, aryl, aralkyl, haloalkyl, or a combination of two or more such groups optionally substituted by oxo, oxo, aryl, thio, halo, amino, hydroxy or by R3; D = H bond donor group (n = 0-2) and their physiol. tolerable salts were prepared as serine protease inhibitors useful as antithrombotic agents. Synthesis methodol. for preparing some I was provided, and common starting materials were Fmoc- or Boc-(D)-phenylglycine and m-amidinobenzoic acid. Descriptions of enzyme assays were given, but no enzyme inhibition data was provided for I. To measure the antithrombotic activity, a partial thromboplastin time test assay was done, and for example, m-amidinobenzoyl-D-phenylglycine ester II (preparation not given, but 1H NMR characterization data provided), at 1.9 μM concentration, doubled the clotting time.


IT 221237-68-9P 221237-74-7P 221237-81-6P  
 221237-90-7P 221237-98-5P 221238-06-8P  
 221240-62-6P 221240-91-1P 221240-97-7P  
 221241-03-8P 221241-09-4P 221241-14-1P

L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)  
 221241-19-6P 221241-24-3P 221241-29-8P  
 221242-18-8P 221242-26-8P 221242-30-4P  
 221242-34-8P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prep. of meta-benzamidine derivs. of amino acids or dipeptides as serine protease inhibitors)

RN 221237-68-9 CAPLUS  
 CN Benzamide, N-[(1R)-2-(4-(4-acetylphenyl)-1-piperazinyl)-2-oxo-1-phenylethyl]-3-(aminoiminomethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 221240-62-6 CAPLUS  
 CN Carbamic acid, [{3-[(1R)-2-{4-(4-chlorophenyl)-1-piperazinyl}-2-oxo-1-phenylethyl]amino}carbonyl]phenyl]iminomethyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221240-91-1 CAPLUS  
 CN Benzamide, 3-(aminoiminomethyl)-N-[(1R)-2-{4-(4-nitrophenyl)-1-piperazinyl}-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221240-97-7 CAPLUS  
 CN Benzamide, 3-(aminoiminomethyl)-N-[(1R)-2-{4-(4-aminophenyl)-1-piperazinyl}-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221241-19-6 CAPLUS  
 CN Benzamide, 3-(aminoiminomethyl)-N-[(1R)-2-oxo-1-phenyl-2-[4-(phenylmethyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221241-24-3 CAPLUS  
 CN Benzamide, 3-(aminoiminomethyl)-N-[(1R)-2-{4-(3-chlorophenyl)-1-piperazinyl}-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221241-29-8 CAPLUS  
 CN Benzamide, 3-(aminoiminomethyl)-N-[(1R)-2-{4-(2-chlorophenyl)-1-piperazinyl}-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221241-03-8 CAPLUS  
 CN Benzamide, 3-(aminoiminomethyl)-N-[(1R)-2-{4-(4-fluorophenyl)-1-piperazinyl}-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221241-09-4 CAPLUS  
 CN Benzamide, 3-(aminoiminomethyl)-N-[(1R)-2-oxo-1-phenyl-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221241-14-1 CAPLUS  
 CN Benzamide, 3-(aminoiminomethyl)-N-[(1R)-2-oxo-1-phenyl-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 221242-18-8 CAPLUS  
 CN Propanoic acid, 2,2-dimethyl-, [{[(3-[(1R)-2-{4-(4-chlorophenyl)-1-piperazinyl}-2-oxo-1-phenylethyl]amino}carbonyl]phenyl}iminomethyl]acarbonyl oxy methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

RN 221242-26-8 CAPLUS  
 CN Carbamic acid, [{3-[(1R)-2-{4-(4-chlorophenyl)-1-piperazinyl}-2-oxo-1-phenylethyl]amino}carbonyl]phenyl]iminomethyl-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 221242-30-4 CAPLUS  
 CN Carbamic acid, [13-[[[(1R)-2-[4-(4-chlorophenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]amino]carbonyl]phenyl]iminomethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221242-34-8 CAPLUS  
 CN Benzamide, 3-[(acetylaminio)iminomethyl]-N-[(1R)-2-[4-(4-chlorophenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN  
 ACCESSION NUMBER: 1999:184268 CAPLUS  
 DOCUMENT NUMBER: 130:223587  
 TITLE: 1-amino-7-isouquinoline derivatives as serine protease inhibitors  
 INVENTOR(S): Liebeschuetz, John Walter; Wylie, William Alexander; Waszkowycz, Bohdan; Murray, Christopher William; Rimmer, Andrew David; Welsh, Pauline Mary; Jones, Stuart Donald; Roscoe, Jonathan Michael Ernest; Young, Stephen Clinton; Morgan, Phillip John; Camp, Nicholas Paul; Crew, Andrew Philip Austin  
 PATENT ASSIGNEE(S): Proteus Molecular Design Ltd., UK  
 SOURCE: PCT Int. Appl., 89 pp.  
 CODEN: PIXX02  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 13  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9911657	A1	19990311	WO 1998-GB2600	19980828
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SZ, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BU, CF, CG, CI, CM, GA, GN, GW, HL, MR, NE, SN, TD, TG				
AU 9888753	A1	19990322	AU 1998-88753	19980828
EP 1012166	A1	20000628	EP 1998-940425	19980828
EP 1012166	B1	20031029		
R: CH, DE, ES, FR, GB, IT, LI, NL				
US 6262069	B1	20010117	US 2000-485677	20000225
US 2002040144	A1	20020404	US 2001-865418	20010529
US 6420438	B1	20020716	US 2002-565418	20020529
US 2003216403	A1	20031120	US 2003-296245	20030514
PRIORITY APPLN. INFO.:				
R: CH, DE, ES, FR, GB, IT, LI, NL				
GB 1997-18392	A	19970829		
GB 1998-3173	A	19980213		
WO 1998-GB2600	W	19980828		
US 2000-485677	A1	20000225		
WO 2001-GB2566	W	20010612		

OTHER SOURCE(S): MARPAT 130:223587  
 GI



L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

AB Aminoisoquinoline amino acid derivs. I (R1 = H, halo, cyano, nitro, hydroxy, amino, alkoxyl, alkyl, aminoalkyl, hydroxalkyl, thiol, alkylthio, aminosulfonyl, alkoxalkyl, alkoxycarbonyl, acyloxymethoxycarbonyl or oxo; and R is X-X'-Y(R7)-L-Lp(D), where each X independently is a C, N, O or S atom or a CO, CR1 or CR1 group; Y is a nitrogen atom or a CR1 group or Y and L taken together form a cyclic group; R7 is a lipophilic group selected from alkyl, alkenyl, mono- or bi-cycloalkyl, aryl, heteroaryl, mono- or bicycloalkylalkyl, mono- or bicycloalkylalkenyl, aralkyl, heteroaryl-alkyl, alkylarenyl, heteroarylalkenyl, all optionally substituted by a group R1; L is an organic linker group containing 1 to 5 backbone atoms selected from C, N, O and S, or a branched alkyl or cyclic group; Lp is a lipophilic organic group selected from alkyl, heterocyclic, alkenyl, alkaryl, cycloalkyl, polycycloalkyl, cycloalkenyl, aryl, aralkyl or haloalkyl group or a combination of two or more such groups optionally substituted by one or more of oxa, thia,aza or R1 groups; D is a hydrogen bond donor group; and n is 0, 1, or 2) or their 3,4-dihydro derivs. were prepared as serine protease inhibitors. Thus, 1-aminoisoquinolin-7-yl-D-phenylglycine 4-methoxybenzylamide was prepared by amidation of Boc-D-phenylglycine with 4-methoxybenzylamine, followed by deprotection and coupling with 1-aminoisoquinolin-7-carboxylic acid trifluoroacetate.

IT 221049-85-0 221049-86-1 221049-87-2P

221049-88-3P 221049-89-4P 221049-90-7P

221049-91-9P 221049-92-9P 221049-93-0P

221049-94-1P 221049-95-2P 221049-96-3P

221050-11-9P 221050-12-0P 221050-13-1P

221050-14-2P 221050-15-4P 221050-16-4P

221050-17-5P 221050-18-6P 221050-19-7P

221050-20-0P 221050-21-1P 221050-22-2P

221050-23-3P 221050-24-4P 221050-25-5P

221050-26-6P 221050-27-7P 221050-28-8P


221050-62-0P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of aminoisoquinoline peptidyl derivs. as serine protease inhibitors)

RN 221049-85-0 CAPLUS

CN 7-isouquinolinelinecarboxamide, 1-amino-N-[(1R)-2-oxo-1-phenyl-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221049-86-1 CAPLUS  
 CN 7-isouquinolinelinecarboxamide, 1-amino-N-[(1R)-2-[(4-aminophenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)


Habte

L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.


RN 221049-87-2 CAPLUS  
 CN 7-isouquinolinelinecarboxamide, 1-amino-N-[(1R)-2-oxo-1-phenyl-2-[4-(4-chlorophenyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221049-88-3 CAPLUS  
 CN 7-isouquinolinelinecarboxamide, 1-amino-N-[(1R)-2-oxo-1-phenyl-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 221049-89-4 CAPLUS  
 CN 7-isouquinolinelinecarboxamide, 1-amino-N-[(1R)-2-oxo-1-phenyl-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

11/23/2004




RN 221049-90-7 CAPLUS  
CN 7-Isouquinolinelinecarboxamide, 1-amino-N-[(1R)-2-oxo-1-phenyl-2-[4-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221049-91-8 CAPLUS  
CN 7-Isouquinolinelinecarboxamide, 1-amino-N-[(1R)-2-[4-(2-methoxyphenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221049-92-9 CAPLUS  
CN 7-Isouquinolinelinecarboxamide, 1-amino-N-[(1R)-2-[4-(2-methylphenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221049-96-3 CAPLUS  
CN 7-Isouquinolinelinecarboxamide, 1-amino-N-[(1R)-2-oxo-1-phenyl-2-[4-(2-pyrimidinyl)-1-piperazinyl]-2-oxo-1-phenylethyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221050-11-9 CAPLUS  
CN 7-Isouquinolinelinecarboxamide, 1-amino-N-[(1R)-2-[4-(4-hydroxyphenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221050-12-0 CAPLUS  
CN 7-Isouquinolinelinecarboxamide, 1-amino-N-[(1R)-2-[4-(4-hydroxyphenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221049-93-0 CAPLUS  
CN 7-Isouquinolinelinecarboxamide, 1-amino-N-[(1R)-2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]-2-oxo-1-phenylethyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




Absolute stereochemistry.




RN 221049-95-2 CAPLUS  
CN 7-Isouquinolinelinecarboxamide, 1-amino-N-[(1R)-2-[4-(2-chlorophenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221050-13-1 CAPLUS  
CN 7-Isouquinolinelinecarboxamide, 1-amino-N-[(1R)-2-[4-(4-nitrophenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221050-14-2 CAPLUS  
CN 7-Isouquinolinelinecarboxamide, 1-amino-N-[(1R)-2-[4-(4-methylphenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221050-15-3 CAPLUS  
CN 7-Isouquinolinelinecarboxamide, 1-amino-N-[(1R)-2-[4-(4-methoxyphenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221050-16-4 CAPLUS  
 CN 7-Isouquinolinecarboxamide, 1-amino-N-[1-(4-(4-fluorophenyl)-2-[4-(4-fluorophenyl)-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 221050-17-5 CAPLUS  
 CN 7-Isouquinolinecarboxamide, 1-amino-N-[1R)-1-cyclohexyl-2-[4-(4-fluorophenyl)-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221050-18-6 CAPLUS  
 CN 7-Isouquinolinecarboxamide, 1-amino-N-[1R)-2-[4-(3-chlorophenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221050-22-2 CAPLUS  
 CN 7-Isouquinolinecarboxamide, 1-amino-N-[1R)-2-[4-(2-hydroxyphenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221050-23-3 CAPLUS  
 CN 7-Isouquinolinecarboxamide, 1-amino-N-[1R)-2-[4-(2,4-difluorophenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221050-24-4 CAPLUS  
 CN 7-Isouquinolinecarboxamide, 1-amino-N-[1R)-2-[4-(2,3-dimethylphenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221050-19-7 CAPLUS  
 CN 7-Isouquinolinecarboxamide, 1-amino-N-[1R)-2-[4-(3-methylphenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221050-20-0 CAPLUS  
 CN 7-Isouquinolinecarboxamide, 1-amino-N-[1R)-2-[4-(3-methoxyphenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221050-21-1 CAPLUS  
 CN 7-Isouquinolinecarboxamide, 1-amino-N-[1R)-2-[4-(2-fluorophenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221050-25-5 CAPLUS  
 CN 7-Isouquinolinecarboxamide, 1-amino-N-[1R)-2-[4-(2,4-dimethylphenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221050-26-6 CAPLUS  
 CN 7-Isouquinolinecarboxamide, 1-amino-N-[1R)-2-[4-(2,6-dimethylphenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 221050-27-7 CAPLUS  
 CN 7-Isouquinolinecarboxamide, 1-amino-N-[1R)-2-[4-(2,5-dimethylphenyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 221050-29-8 CAPLUS  
 CN 7-Isquinolinecarboxamide, 1-amino-N-[(1R)-1-cyclohexyl-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221050-62-0 CAPLUS  
 CN 7-Isquinolinecarboxamide, 1-amino-N-[(1R)-2-oxo-1-phenyl-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN  
 ACCESSION NUMBER: 1998:65811 CAPLUS  
 DOCUMENT NUMBER: 128:136515  
 TITLE: Bone resorption inhibitors  
 INVENTOR(S): Aiba, Kazuhiko; Takebayashi, Yukihiko; Ishii, Yasutaka; Noshiro, Osamu; Noda, Ichio; Igarashi, Susumu  
 PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 105 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9801133	A1	19980115	WO 1997-JP2357	19970708
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GE, GH, HU, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BE, BJ, CF, CG, CI, CH, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9733596	A1	19980202	AU 1997-33596	19970708
PRIORITY APPN. INFO.:			JP 1996-177955	19960708
OTHER SOURCE(S):			WO 1997-JP2357	19970708
GI			MARPAT 128:136515	



AB Drugs, in particular, bone resorption inhibitors containing as the active ingredient compds. having selective cathepsin K inhibitory effects, among all, proline derivs. represented by general formula (I) or pharmaceutically acceptable salts thereof, wherein each symbol has the meaning as specified below: X: a moiety (except for the C-terminal carbonyl group) of an amino acid residue with its side chain optionally protected; R1: an amino-protective group; G: a glycine residue; n: 0 or 1; R3: a group inhibiting the activity of the SH group of cysteine protease; and R4: hydrogen, hydroxy or Ph.  
 IT 202281-95-6P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (bone resorption inhibitors)

L4 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)  
 RN 202281-95-6 CAPLUS  
 CN 1-Pyrrolidinocarboxylic acid, 2-[(2-oxo-1-phenyl-2-(1-piperazinyl)ethyl)amino]carbonyl-, phenylmethyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN  
 ACCESSION NUMBER: 1991:656227 CAPLUS  
 DOCUMENT NUMBER: 115:256227  
 TITLE: Preparation of alkylpiperazines as cyclooxygenase and lipoxygenase inhibitors  
 INVENTOR(S): Suzuki, Masahiro; Nozaki, Kenji; Kajitani, Makoto; Yasumoto, Mitsuji; Ono, Naohiko; Shindo, Takashi  
 PATENT ASSIGNEE(S): Taiho Pharmaceutical Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 97 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9111444	A1	19910808	WO 1991-JP60	19910119
W: AU, CA, JP, KR, US RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
CA 2050492	AA	19910727	CA 1991-2050492	19910119
CA 2050492	C	19961217		
AU 9170576	A1	19910821	AU 1991-70576	19910119
AU 637670	B2	19930603		
EP 465659	A1	19920115	EP 1991-902742	19910119
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE US 5182284				
US 5182284	A	19930126	US 1991-761974	19910295
PRIORITY APPN. INFO.:			JP 1990-16583	19900126
OTHER SOURCE(S):			WO 1991-JP60	19910119
GI				



AB The title compds. [I; R, R1 = OH, alkoxy, halo, H, dialkyl phosphate residue, etc.; or R1 = OCH2; Y = CH:CH, (CH2)m = 0, 1; Y1 = Q, Q1; A = NH, O; A1 = CH2, CO; n = 6-20; X = OH, H, alkoxy carbonyl; X1 = H, (halo)phenyl; however, when Y1 = Q1, R = R1 = OH] and their pharmaceutically acceptable salts, inhibitors of particularly 5-lipoxygenase, useful for treatment of asthma, etc., are prepared stirring a mix of (hydroxymethyl)piperazine II [R2 = H, R3 = tetrahydro-2-pyranyl] with cinnamic acid in CH2Cl2 containing 4-(dimethylamino)pyridine and dicyclohexylcarbodiimide at room temperature for 24 h gave, after deprotection by refluxing in MeOH containing p-MeC6H4CO3H, 69% title compound II [R2 = cinnamoyl, R3 = H]. The IC50 values for the title compound II [R2 = 3,4-(OH)2C6H4CH2CO, R3 = H] are 9.9 and 0.32  $\mu$ M against cyclooxygenase and 5-lipoxygenase, resp. Tablets, granules, capsules, etc., containing I


11/23/2004

Habte

L4 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)  
 L4 were formulated.  
 IT 137424-14-7P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of, as cyclooxygenase and lipoxygenase inhibitors)  
 RN 137424-14-7 CAPLUS  
 CN Benzanide, N-[2-(4-decyl-1-piperazinyl)-2-oxo-1-phenylethyl]-3,4-dihydroxy-  
 (2Z)-2-butenedioato (1:1) (salt) (SICI) [CA INDEX NAME]

CM 1

CRN 137424-13-6  
CMF C29 H41 N3 04



CRN 110-16-7  
CMF C4 H4 04

Double bond geometry as shown.

